

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12N 15/45, A61K 39/155 G01N 33/569	A1	(11) International Publication Number: WO 93/14207 (43) International Publication Date: 22 July 1993 (22.07.93)
(21) International Application Number: PCT/CA93/00001 (22) International Filing Date: 5 January 1993 (05.01.93)		(74) Agent: STEWART, Michael, I.; Sim & McBurney, 330 University Avenue, Suite 701, Toronto, Ontario M5A 1R7 (CA).
(30) Priority data: 9200117.1 6 January 1992 (06.01.92) GB		(81) Designated States: AU, BR, CA, FI, JP, KR, NO, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(71) Applicant (for all designated States except US): CONNAUGHT LABORATORIES LIMITED [CA/CA]; 1755 Steeles Avenue West, Willowdale, Ontario M2R 3T4 (CA).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(72) Inventors; and (75) Inventors/Applicants (for US only) : KLEIN, Michel, H. [CA/CA]; 16 Monro Boulevard, Willowdale, Ontario L4Z 1M5 (CA). DU, Run-Pan [CA/CA]; 299 Chelwood Drive, Thornhill, Ontario L4J 7Y8 (CA). EWASYSYHYN, Mary, E. [CA/CA]; 120 Torresdale, Apartment 1506, Willowdale, Ontario M2R 3N7 (CA).		
(54) Title: CHIMERIC IMMUNOGENS		
(57) Abstract <p>Multimeric hybrid genes encoding the corresponding chimeric protein comprise a gene sequence coding for an antigenic region of a protein from a first pathogen linked to a gene sequence coding for an antigenic region of a protein from a second pathogen. The pathogens particularly are parainfluenza virus (PIV) and respiratory syncytial virus (RSV). A single recombinant immunogen is capable of protecting infants and similar susceptible individuals against diseases caused by both PIV and RSV.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	CN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CC	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

CHIMERIC IMMUNOGENSFIELD OF INVENTION

5 The present invention relates to the engineering and expression of multimeric hybrid genes containing sequences from the gene coding for immunogenic proteins or protein fragments of numerous pathogens.

BACKGROUND TO THE INVENTION

10 The advantage of the approach taken by the present invention is to produce single immunogens containing protective antigens from a range of pathogens. Such chimeras greatly simplify the development of combination vaccines, in particular, with the view ultimately to 15 produce single dose multivalent vaccines. Multivalent vaccines are currently made by separately producing pathogens and/or their pertinent antigens and combining them in various formulations. This is a labour intensive, costly and complex manufacturing procedure.

20 In contrast, the availability of a single immunogen capable of protecting against a range of diseases would solve many of the problems of multivalent vaccine production. Several chimeric immunogens of the type provided herein may be combined to decrease the number of 25 individual antigens required in a multivalent vaccine.

Human Parainfluenza virus types 1,2,3 and Respiratory syncytial virus types A and B are the major viral pathogens responsible for causing severe respiratory tract infections in infants and young 30 children. It is estimated that, in the United States alone, approximately 1.6 million infants under one year of age will have a clinically significant RSV infection each year and an additional 1.4 million infants will be infected with PIV-3. Approximately 4000 infants less 35 than one year of age in the United States die each year from complications arising from severe respiratory tract disease caused by infection with RSV and PIV-3. The WHO

and NIAID vaccine advisory committees ranked RSV number two behind HIV for vaccine development while the preparation of an efficacious PIV-3 vaccine is ranked in the top ten vaccines considered a priority for vaccine development.

Safe and effective vaccines for protecting infants against these viral infections are not available and are urgently required. Clinical trials have shown that formaldehyde-inactivated and live-attenuated viral vaccines failed to adequately protect vaccinees against these infections. In fact, infants who received the formalin-inactivated RSV vaccine developed more serious lower respiratory tract disease during subsequent natural RSV infection than did the control group. [Am. J. Epidemiology 89, 1969, p.405-421; J. Inf. Dis. 145, 1982, p.311-319]. Furthermore, RSV glycoproteins purified by immunoaffinity chromatography using elution at acid pH induced immunopotentiation in cotton rats. [Vaccine, 10(7), 1992, p.475-484]. The development of efficacious PIV-3 and RSV vaccines which do not cause exacerbated pulmonary disease in vaccinees following injection with wild-type virus would have significant therapeutic implications. It is anticipated that the development of a single recombinant immunogen capable of simultaneously protecting infants against diseases caused by infection with both Parainfluenza and Respiratory syncytial viruses could significantly reduce the morbidity and mortality caused by these viral infections.

It has been reported that a protective response against PIV-3 and RSV is contingent on the induction of neutralizing antibodies against the major viral surface glycoproteins. For PIV, these protective immunogens are the HN protein which has a molecular weight of 72 kDa and possesses both hemagglutination and neuraminidase activities and the fusion (F) protein, which has a molecular weight of 65 kDa and which is responsible for

both fusion of the virus to the host cell membrane and cell-to-cell spread of the virus. For RSV, the two major immunogenic proteins are the 80 to 90 kDa G glycoprotein and the 70 kDa fusion (F) protein. The G and F proteins
5 are thought to be functionally analogous to the PIV HN and F proteins, respectively. The PIV and RSV F glycoproteins are synthesized as inactive precursors (FO) which are proteolytically cleaved into N-terminal F2 and C-terminal F1 fragments which remain linked by disulphide
10 bonds.

Recombinant surface glycoproteins from PIV and RSV have been individually expressed in insect cells using the baculovirus system [Ray et al., (1989), Virus Research, 12: 169-180; Coelingh et al., (1987), Virology, 160: 465-472; Wathen et al., (1989), J. of Inf. Dis. 159: 253-263] as well as in mammalian cells infected with recombinant poxviruses [Spriggs, et al., (1987), J. Virol. 61: 3416-3423; Stott et al., (1987), J. Virol. 61: 3855-3861]. Recombinant antigens produced in these
20 systems were found to protect immunized cotton rats against live virus challenge. More recently, hybrid RSV F-G [Wathan et al., (1989), J. Gen Virol. 70: 2625-2635; Wathen, published International Patent application WO 89/05823] and PIV-3 F-HN [Wathen, published International
25 Patent Application WO 89/10405], recombinant antigens have been engineered and produced in mammalian and insect cells. The RSV F-G hybrid antigen was shown to be protective in cotton rats [Wathan et al., (1989), J. Gen. Virol. 70: 2637-2644] although it elicited a poor anti-G
30 antibody response [Connors et al., (1992), Vaccine 10: 475-484]. The protective ability of the PIV-3 F-HN protein was not reported in the published patent application. These antigens were engineered with the aim to protect against only the homologous virus, that is either RSV or PIV-3. However, it would be advantageous
35 and economical to engineer and produce a single

recombinant immunogen containing at least one protective antigen from each virus in order simultaneously to protect infants and young children against both PIV and RSV infections. The chimeric proteins provided herein for such purpose also may be administered to pregnant women or women of child bearing age to stimulate maternal antibodies to both PIV and RSV. In addition, the vaccine also may be administered to other susceptible individuals, such as the elderly.

10

SUMMARY OF INVENTION

hybrid gene, which may be a viral vector or a bacterial vector, and a physiologically-acceptable carrier therefor. Such live vector may form the active component of a vaccine against diseases caused by multiple pathogenic infections. Such vaccine may be formulated to be administered in an injectable form, intranasally or orally.

In an additional aspect of the present invention, there is provided a process for the preparation of a chimeric protein, which comprises isolating a gene sequence coding for an antigenic region of a protein from a first pathogen; isolating a gene sequence coding for an antigenic region of a protein from a second pathogen; linking the gene sequences to form a multimeric hybrid gene; and expressing the multimeric hybrid gene in a cellular expression system. Such cellular expression system may be provided by bacterial cells, mammalian cells, insect cells, yeast cells or fungal cells. The chimeric protein product of gene expression may be separated from a culture of the cellular expression system and purified.

The present invention further includes a vaccine against diseases caused by multiple pathogen infections, comprising the chimeric protein encoded by the multimeric hybrid gene and a physiologically-acceptable carrier therefor. Such vaccine may be formulated to be administered in an injectable form, intranasally or orally.

The vaccines provided herein may be used to immunize a host against disease caused by multiple pathogenic infections, particularly those caused by a parainfluenza virus and respiratory syncytial virus, by administering an effective amount of the vaccine to the host. As noted above, for human PIV and RSV, the host may be infants and young children, pregnant women as well as those of a

child-bearing age, and other susceptible persons, such as the elderly.

The chimeric protein provided herein also may be used as a diagnostic reagent for detecting infection by 5 a plurality of different pathogens in a host, using a suitable assaying procedure.

It will be appreciated that, while the description of the present invention which follows focuses mainly on a chimeric molecule which is effective for immunization 10 against diseases caused by infection by PIV and RSV, nevertheless the invention provided herein broadly extends to any chimeric protein which is effected for immunization against diseases caused by a plurality of pathogens, comprising an antigen from each of the 15 pathogens linked in a single molecule, as well as to genes coding for such chimeric molecules.

In this application, by the term "multimeric hybrid genes" we mean genes encoding antigenic regions of proteins from different pathogens and by the term 20 "chimeric proteins" we mean immunogens containing antigenic regions from proteins from different pathogens.

BRIEF DESCRIPTION OF DRAWINGS

Figure 1 shows the nucleotide (SEQ ID No: 1) and amino acid (SEQ ID No: 2) sequence of a PCR-amplified 25 PIV-3 F gene and F protein, respectively;

Figure 2 shows the restriction map of the PIV-3 F gene;

Figure 3 shows the nucleotide (SEQ ID No: 3) and amino acid (SEQ ID No: 4) sequences of the PIV-3 HN gene 30 and HN protein, respectively;

Figure 4 shows the restriction map of the PIV-3 HN gene;

Figure 5 shows the nucleotide (SEQ ID No: 5) and amino acid (SEQ ID No: 6) sequences of the RSV F gene and 35 RSV F protein, respectively;

Figure 6 shows the restriction map of the RSV F gene;

Figure 7 shows the nucleotide (SEQ ID No: 7) and amino acid (SEQ ID No: 8) sequences of the RSV G gene and
5 RSV G protein, respectively;

Figure 8 shows the restriction map of the RSV G gene;

Figure 9 shows the steps involved in the construction of an expression vector containing a
10 chimeric F_{PIV-3} - F_{RSV} gene;

Figure 10 shows the steps involved in the construction of an expression vector containing a F_{PIV-3} gene lacking the 5'-untranslated sequence and transmembrane anchor and cytoplasmic tail coding regions;

15 Figure 11 shows the steps involved in the construction of an expression vector containing a chimeric F_{PIV-3} - F_{RSV} gene containing a truncated PIV-3 F gene devoid of 5'-untranslated region linked to a truncated RSV F1 gene;

20 Figure 12 shows the steps involved in construction of a modified pAC 610 baculovirus expression vector containing a chimeric F_{PIV-3} - F_{RSV} gene consisting of the PIV-3 F gene lacking both the 5'-untranslated sequence as well as transmembrane and cytoplasmic tail coding region
25 linked to the truncated RSV F1 gene;

Figure 13 shows immunoblots of cell lysates from Sf9 cells infected with recombinant baculoviruses;

Figure 14 shows the steps involved in constructing a baculovirus transfer vector (pD2);

30 Figure 15 shows the steps involved in construction of a chimeric F_{RSV} - HN_{PIV-3} gene;

Figure 16 shows an SDS-PAGE gel and immunoblot of purified F_{RSV} - HN_{PIV-3} chimeric protein;

Figure 17 illustrates mutagenesis of a PIV-3 F gene;

35 and

Figure 18 shows the steps involved in the construction of a chimeric $F_{PIV-3} - G_{RSV}$ gene.

GENERAL DESCRIPTION OF INVENTION

5 In the present invention, a chimeric molecule protective against two different major childhood diseases is provided. The present invention specifically relates to the formulation of various recombinant Parainfluenza virus (PIV)/Respiratory syncytial virus (RSV) immunogens 10 to produce safe and efficacious vaccines capable of protecting infants and young children, as well as other susceptible individuals, against diseases caused by infection with both PIV and RSV. However, as described above, the present invention extends to the construction 15 of multimeric hybrid genes containing genes coding for protective antigens from many pathogens. Such vaccines may be administered in any desired manner, such as a readily-injectable vaccine, intranasally or orally.

In the present invention, the inventors have 20 specifically engineered several model PIV/RSV chimeric genes containing relevant sequences from selected genes coding for PIV-3 and RSV surface glycoproteins linked in tandem. All genes in the chimeric constructs described herein were obtained from recent clinical isolates of 25 PIV-3 and RSV. The chimeric gene constructs may include gene sequences from either PIV-3 F or HN genes linked in tandem to either RSV F or G genes in all possible relative orientations and combinations.

The chimeric gene constructs provided herein may 30 consist of either the entire gene sequences or gene segments coding for immunogenic and protective epitopes thereof. The natural nucleotide sequence of these genes may be modified by mutation while retaining antigenicity and such modifications may include the removal of 35 putative pre-transcriptional terminators to optimize their expression in eukaryotic cells. The genes were

designed to code for hybrid PIV-RSV surface glycoproteins linked in tandem in a single construct to produce gene products which elicit protective antibodies against both parainfluenza and respiratory syncytial viruses. Such

5 multimeric hybrid genes consist of a gene sequence coding for a human PIV-3 F or HN protein or an immunogenic epitope-containing fragment thereof linked to a gene sequence coding for a human RSV G or F protein or an immunogenic epitope-containing fragment thereof.

10 Specific gene constructs which may be employed include $F_{PIV-3} - F_{RSV}$, $F_{RSV} - HN_{PIV-3}$ and $F_{PIV-3} - G_{RSV}$ hybrid genes.

In addition, the present invention also extends to the construction of other multimeric genes, such as trimeric genes containing PIV and RSV genes or gene segments, linked in all possible relative orientations.

15 For example:

$F_{PIV} - HN_{PIV} - F$ or G_{RSV}

$F_{PIV} - F_{RSV} - G_{RSV}$

$HN_{PIV} - F_{RSV} - G_{RSV}$

20 The multimeric genes provided herein also may comprise at least one gene encoding at least one immunogenic and/or immunostimulating molecule.

The multimeric hybrid genes provided herein may be sub-cloned into appropriate vectors for expression in cellular expression systems. Such cellular expression systems may include bacterial, mammalian, insect and fungal, such as yeast, cells.

25 The chimeric proteins provided herein also may be presented to the immune system by the use of a live vector, including live viral vectors, such as recombinant poxviruses, adenoviruses, retroviruses, Semliki Forest viruses, and live bacterial vectors, such as *Salmonella* and mycobacteria (e.g. BCG).

30 Chimeric proteins, such as a PIV/RSV chimera, present in either the supernatants or cell lysates of

transfected, transformed or infected cells then can be purified in any convenient manner.

To evaluate the immunogenicity and protective ability of the chimeric proteins, suitable experimental animals are immunized with either varying doses of the purified chimeric proteins, such as the PIV/RSV chimera, and/or live recombinant vectors as described above. Such chimeric proteins may be presented to the immune system by either the use of physiologically-acceptable vehicles, such as aluminum phosphate, or by the use of delivery systems, such as ISCOMS and liposomes. The chimeras also may be formulated to be capable of eliciting a mucosal response, for example, by conjugation or association with immunotargeting vehicles, such as the cholera toxin B subunit, or by incorporation into microparticles. The vaccines may further comprise means for delivering the multimeric protein specifically to cells of the immune system, such as toxin molecules or antibodies. To further enhance the immunoprotective ability of the chimeric proteins, they may be supplemented with other immunogenic and/or immunostimulating molecules. The chimeric PIV/RSV proteins specifically described herein may be formulated with an adjuvant, such as aluminum phosphate, to produce readily-injectable vaccines for protection against the diseases caused by both PIV-3 and RSV. The chimeric proteins also may be administered intranasally or orally. The chimeric proteins may be used in test kits for diagnosis of infection by PIV-3 and RSV.

The invention is not limited to the preparation of chimeric PIV-3 and RSV proteins, but is applicable to the production of chimeric immunogens composed of either the entire sequences or regions of the immunogenic proteins from at least two pathogens sequentially linked in a single molecule. Chimeric antigens also may be synthesized to contain the immunodominant epitopes of

11

several proteins from different pathogens. These chimeric antigens may be useful as vaccines or as diagnostic reagents.

SEQUENCE IDENTIFICATION

5 Several nucleotide and amino acid sequences are referred to in the disclosure of this application. The following table identifies the sequences and the location of the sequence:

10	<u>SEQ ID No.</u>	<u>Identification</u>	<u>Location</u>
15	1	Nucleotide sequence for PCR-amplified PIV-3 F gene	Fig. 1, Example 1
20	2	Amino acid sequence for PCR-amplified PIV-F protein	Fig. 1, Example 1
25	3	Nucleotide sequence for PIV-3 HN gene	Fig. 3, Example 1
30	4	Amino acid sequence for PIV-3 HN protein	Fig. 3, Example 1
35	5	Nucleotide sequence for RSV F gene	Fig. 5, Example 1
40	6	Amino acid sequence for RSV F protein	Fig. 5, Example 1
45	7	Nucleotide sequence for RSV G gene	Fig. 7, Example 1
50	8	Amino acid sequence for RSV G protein	Fig. 7, Example 1
	9	BsrI - BamHI oligo-nucleotide cassette	Fig. 9, Example 2
	10	BspHI - BamHI oligo-nucleotide cassette	Fig. 9, Example 2
	11	EcoRI - Ppu MI oligo-nucleotide cassette	Fig. 9, Example 2
	12	BrsI - BamHI oligo-nucleotide cassette	Fig. 10, Example 3

12

- 13 EcoRI -Bsr BI oligo-nucleotide cassette Fig. 10, Example 3
- 5 14 EcoRV - EcoRI oligo-nucleotide cassette Fig. 11, Example 5
- 15 EcoRV - BamHI oligo-nucleotide cassette Fig. 14, Example 8
- 10 16 BspHI - BspHI oligo-nucleotide cassette Fig. 15, Example 9
- 15 17 Nucleotide sequence for PIV-3 F gene Example 15
- 18 Mutagenic oligo-nucleotide #2721 Fig. 17, Example 15
- 20 19 Nucleotide sequence for part of oligo-nucleotide #2721 Example 15
- 25 20 Oligonucleotide probe Example 15

DEPOSIT INFORMATION

Certain plasmid DNAs described and referred to herein have been deposited with the American Type Culture Collection (ATCC) located at Rockville, Maryland, USA, pursuant to the Budapest Treaty and prior to the filing of this application. The deposited purified plasmids will become available to the public upon grant of this U.S. patent application or upon publication of its corresponding European patent application, whichever first occurs. The invention described and claimed herein is not to be limited in scope by the plasmid DNAs of the constructs deposited, since the deposited embodiment is intended only as an illustration of the invention. The following purified plasmids were deposited at the ATCC with the noted accession numbers on December 17, 1992:

<u>Plasmid</u>	<u>Example No.</u>	<u>Accession No.</u>
pAC DR7	5	75387
pD2RF-HN	9	75388
pD2F-G	16	75389

Any equivalent plasmids that can be used to produce equivalent antigens as described in this application are within the scope of the invention.

EXAMPLES

5 The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for purposes of illustration and are not intended to limit the scope of 10 the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitations.

15 Methods for cloning and sequencing the PIV-3 and RSV genes as well as the procedures for sub-cloning the genes into appropriate vectors and expressing the gene constructs in mammalian and insect cells are not explicitly described in this disclosure but are well 20 within the scope of those skilled in the art.

Example 1:

25 This Example outlines the strategy used to clone and sequence the PIV-3 F, HN and RSV F, G genes (from a type A isolate). These genes were used in the construction of the F_{PIV-3} - F_{RSV} , $F_{RSV}-HN_{PIV-3}$, and $F_{PIV-3}-G_{RSV}$ chimeric genes detailed in Examples 2 to 4, 9 and 15, respectively.

30 Two PIV-3 F gene clones initially were obtained by PCR amplification of cDNA derived from viral RNA extracted from a recent clinical isolate of PIV-3. Two other PIV-3 F gene clones as well as the PIV-3 HN, RSV F and RSV G genes were cloned from a cDNA library prepared from mRNA isolated from MRC-5 cells infected with clinical isolates of either PIV-3 or RSV (type A isolate). The PIV-3 F (both PCR amplified and non-PCR amplified), PIV-3 HN, RSV F and RSV G gene clones were 35 sequenced by the dideoxynucleotide chain termination

procedure. Sequencing of both strands of the genes was performed by a combination of manual and automated sequencing.

The nucleotide (SEQ ID No: 1) and amino acid (SEQ ID No: 2) sequences of the PCR amplified PIV-3 F gene and F protein, respectively, are presented in Figure 1 and the restriction map of the gene is shown in Figure 2. Sequence analysis of the 1844 nucleotides of two PCR amplified PIV-3 F gene clones confirmed that the clones were identical. Comparison of the coding sequence of the PCR-amplified PIV-3 F gene clone with that of the published PIV-3 F gene sequence revealed a 2.6% divergence in the coding sequence between the two genes resulting in fourteen amino acid substitutions.

The nucleotide sequence of the non-PCR amplified PIV-3 F gene clone differed from the PCR amplified gene clone in the following manner: the non-PCR amplified clone had ten additional nucleotides (AGGACAAAAG) at the 5' untranslated region of the gene and differed at four positions, 8 (T in PCR-amplified gene to C in non-PCR amplified gene) , 512 (C in PCR-amplified gene to T in non-PCR amplified gene) , 518 (G in PCR-amplified gene to A in non-PCR amplified gene) and 1376 (A in PCR-amplified gene to G in non-PCR amplified gene). These changes resulted in three changes in the amino acid sequence of the F protein encoded by the non-PCR amplified PIV-3 F gene. Serine (position 110), glycine (position 112), and aspartic acid (position 398) in the primary amino acid sequence of the F protein encoded by the PCR amplified PIV-3 F gene was changed to phenylalanine (position 110), glutamic acid (position 112) and glycine (position 398), respectively, in the primary amino acid sequence of the F protein encoded by the PCR amplified clone.

Figure 3 shows the nucleotide (SEQ ID No: 3) and amino acid (SEQ ID No: 4) sequences of the PIV-3 HN gene and protein, respectively and the restriction map of the

gene is presented in Figure 4. Analysis of the 1833 nucleotide sequence from two HN clones confirmed that the sequences were identical. A 4.4% divergence in the coding sequence of the PIV-3 HN gene was noted when the 5 sequence was compared to the published PIV-3 HN coding sequence. This divergence resulted in seventeen amino acid substitutions in the amino acid sequence of the protein encoded by the PIV-3 HN gene.

The nucleotide (SEQ ID No: 5) and amino acid (SEQ ID 10 No: 6) sequences of the RSV F gene and RSV F protein, respectively, are shown in Figure 5 and the restriction map of the gene is shown in Figure 6. Analysis of the 1887 nucleotide sequence from two RSV F clones verified complete sequence homology between the two clones. 15 Comparison of this nucleotide sequence with that reported for the RSV F gene revealed approximately 1.8% divergence in the coding sequence resulting in eleven amino acid substitutions.

The nucleotide (SEQ ID No: 7) and amino acid (SEQ ID 20 No: 8) sequences of the RSV G gene and RSV G protein, respectively, are presented in Figure 7 while the restriction map of the gene is outlined in Figure 8. Comparison of the 920 nucleotide sequence of the G gene clone with the published G sequence (type A isolate) 25 revealed a 4.2% divergence in the nucleotide sequence and a 6.7% divergence in the amino acid sequence of the gene product. This divergence resulted in twenty amino acid substitutions.

The full-length PIV-3 F (non-PCR amplified), PIV-3 30 HN, RSV F and RSV G genes were cloned into λgt11 and subcloned into the multiple cloning site of a Bluescript M13-SK vector, either by blunt end ligation or using appropriate linkers. The PCR-amplified PIV-3 F gene was directly cloned into the Bluescript vector. The cloning 35 vectors containing the PIV-3 F-PCR amplified, PIV-3 F non-PCR amplified, PIV-3 HN, RSV F and RSV G genes were

named pPI3F, pPI3Fc, pPIVHN, pRSVF and pRSVG, respectively.

Example 2:

This Example illustrates the construction of a Bluescript-based expression vector (pMCR20) containing the chimeric F_{PIV-3} - F_{RSV} gene. This chimeric gene construct contains the 5' untranslated region of the PIV-3 F gene but lacks the hydrophobic anchor and cytoplasmic tail coding regions of both the PIV-3 and RSV F genes. The steps involved in the construction of this plasmid are summarized in Figure 9.

To prepare the PIV-3 portion of the chimeric gene (Figure 9, step 1), the full length PIV-3 gene lacking the transmembrane region and cytoplasmic tail coding regions was retrieved from plasmid pPI3F by cutting the polylinker with BamHI, blunt-ending the linearized plasmid with Klenow polymerase and cutting the gene with BsrI. A BsrI-BamHI oligonucleotide cassette (SEQ ID No: 9) containing a PpuMI site and three successive translational stop codons were ligated to the truncated 1.6 Kb [BamHI]-BsrI PIV-3 F gene fragment and cloned into the EcoRV-BamHI sites of a Bluescript M13-SK expression vector containing the human methallothionen promoter and the poly A and IVS sequences of the SV40 genome (designated pMCR20), to generate plasmid pME1.

To engineer the RSV F gene component of the chimeric construct (Figure 9, step 2), the RSV F gene lacking the transmembrane region and cytoplasmic tail coding regions was retrieved from plasmid pRSVF by cutting the polylinker with EcoRI and the gene with BspHI. A synthetic BspHI-BamHI oligonucleotide cassette (SEQ ID No: 10) containing three successive translational stop codons was ligated to the 1.6 Kb truncated RSV F gene and cloned into the EcoRI-BamHI sites of the Bluescript based expression vector, pMCR20 to produce plasmid pES13A. Plasmid pES13A then was cut with EcoRI and PpuMI to

remove the leader and F2 coding sequences from the truncated RSV F gene. The leader sequence was reconstructed using an EcoRI-PpuMI oligocassette (SEQ ID No: 11) and ligated to the RSV F1 gene segment to generate plasmid pES23A.

To prepare the chimeric $F_{PIV-3}-F_{RSV}$ gene (Figure 9, step 3) containing the 5' untranslated region of the PIV-3 F gene linked to the truncated RSV F1 gene fragment, plasmid pME1 (containing the 1.6 Kb truncated PIV-3 F gene) first was cut with PpuMI and BamHI. The PpuMI-BamHI restricted pME1 vector was dephosphorylated with intestinal alkaline phosphatase. The 1.1 Kb RSV F1 gene fragment was retrieved from plasmid pES23A by cutting the plasmid with PpuMI and BamHI. The 1.1 Kb PpuMI-BamHI RSV F1 gene fragment was cloned into the PpuMI-BamHI sites of the dephosphorylated pME1 vector to generate plasmid pES29A. This chimeric gene construct contains the 5' untranslated region of the PIV-3 F gene but lacks the nucleotide sequences coding for the hydrophobic anchor domains and cytoplasmic tails of both the PIV-3 and RSV F proteins.

Example 3:

This Example illustrates the construction of a Bluescript-based expression vector containing the PIV-3 F gene lacking both the 5' untranslated and transmembrane anchor and cytoplasmic tail coding regions. The steps involved in constructing this plasmid are outlined in Figure 10.

Plasmid pPI3F containing the full length PIV-3 F gene was cut with BamHI, blunt ended with Klenow polymerase and then cut with Bsrl to remove the transmembrane and cytoplasmic tail coding regions. The Bluescript-based expression vector, pMCR20, was cut with SmaI and BamHI. A synthetic Bsrl-BamHI oligonucleotide cassette (SEQ ID No: 12) containing a translational stop codon was ligated with the 1.6 Kb blunt ended-Bsrl PIV-3

F gene fragment to the SmaI-BamHI restricted pMCR20 vector to produce plasmid pMpFB. The PIV-3 F gene of this construct lacked the DNA fragment coding for the transmembrane and cytoplasmic anchor domains but 5 contained the 5' untranslated region. To engineer a plasmid containing the PIV-3 F gene devoid of both the 5' untranslated region and the DNA fragment coding for the hydrophobic anchor domain, plasmid pMpFB was cut with EcoRI and BstBI. An EcoRI-BstBI oligocassette (SEQ ID 10 No: 13) containing the sequences to reconstruct the signal peptide and coding sequences removed by the EcoRI-BstBI cut was ligated to the EcoRI-BstBI restricted pMpFB vector to produce plasmid pMpFA.

Example 4:

15 This Example illustrates the construction of the chimeric $F_{PIV-3}-F_{RSV}$ gene composed of the truncated PIV-3 F gene devoid of the 5' untranslated region linked to the truncated RSV F1 gene. The steps involved in constructing this plasmid are summarized in Figure 11.

20 To prepare this chimeric gene construct, plasmid pES29A (Example 2) was cut with BstBI and BamHI to release the 2.5 Kb BstBI-BamHI PI3-3 F-RSV F1 chimeric gene fragment. This BstBI-BamHI fragment was isolated from a low melting point agarose gel and cloned into the 25 BstBI-BamHI sites of the dephosphorylated vector pMpFA to produce plasmid pES60A. This construct contained the PIV-3 F gene lacking both the 5' untranslated region and the hydrophobic anchor and cytoplasmic tail coding sequences linked to the F1 coding region of the truncated 30 RSV F gene. This chimeric gene was subsequently subcloned into the baculovirus transfer vector (see Example 5).

Example 5:

35 This Example illustrates the construction of the modified pAC 610 baculovirus transfer vector containing the native polyhedrin promoter and the chimeric $F_{PIV-3}-F_{RSV}$

gene consisting of the PIV-3 F gene lacking both the 5' untranslated sequence and the nucleotide sequence coding for the hydrophobic anchor domain and cytoplasmic tail linked to the truncated RSV F1 gene. Construction of 5 this plasmid is illustrated in Figure 12.

The pAC 610 baculovirus expression vector was modified to contain the native polyhedrin promoter in the following manner. Vector pAC 610 was cut with EcoRV and BamHI. The 9.4 Kb baculovirus transfer vector lacking 10 the EcoRV-BamHI DNA sequence was isolated from a low melting point agarose gel and treated with intestinal alkaline phosphatase. In a 3-way ligation, an EcoRV-EcoRI oligonucleotide cassette (SEQ ID No: 14) containing the nucleotides required to restore the native polyhedrin 15 promoter was ligated with the 1.6 Kb EcoRI-BamHI truncated RSV F gene fragment isolated from construct pES13A (Example 2, step 2) and the EcoRV-BamHI restricted pAC 610 phosphatased vector to generate plasmid pES47A. To prepare the pAC 610 based expression vector containing 20 the chimeric F_{PIV-3} - F_{RSV} gene, plasmid pES47A was first cut with EcoRI and BamHI to remove the 1.6 Kb truncated RSV F gene insert. The 2.8 Kb F_{PIV-3} - F_{RSV} chimeric gene was retrieved by cutting plasmid pES60A (Example 4) with 25 EcoRI and BamHI. The 2.8 Kb EcoRI-BamHI chimeric gene was ligated to the EcoRI-BamHI restricted pES47A vector to generate plasmid pAC DR7 (ATCC 75387).

Example 6

This Example outlines the preparation of plaque-purified recombinant baculoviruses containing the 30 chimeric F_{PIV-3} - F_{RSV} gene.

Spodoptera frugiperda (Sf9) cells were co-transfected with 1.0 μ g wild-type AcMNPV DNA and 2.5 μ g of F_{PIV-3} - F_{RSV} plasmid DNA (plasmid pAC DR7 - Example 5). Putative recombinant baculoviruses (purified once by 35 serial dilution) containing the F_{PIV-3} - F_{RSV} chimeric gene were identified by dot-blot hybridization. Lysates of

insect cells infected with the putative recombinant baculoviruses were probed with the ^{32}P -labelled $\text{F}_{\text{PIV-3}}-\text{F}_{\text{RSV}}$ chimeric gene insert. Recombinant baculoviruses were plaque-purified twice before being used for expression studies. All procedures were carried out according to the protocols outlined by M.D. Summers and G.E. Smith in "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures", Texas Agricultural Experiment Station, Bulletin 1555, 1987.

10 Example 7:

This Example illustrates the presence of the chimeric $\text{F}_{\text{PIV-3}}-\text{F}_{\text{RSV}}$ protein in supernatants and cell lysates of infected Sf9 cells.

Insect cells were infected with the plaque-purified recombinant baculoviruses prepared as described in Example 6 at a m.o.i. of 8. Concentrated supernatants from cells infected with the recombinant viruses were positive in a PIV-3 F specific ELISA. In addition, when lysates from ^{35}S -methionine labelled infected cells were subjected to SDS-polyacrylamide gel electrophoresis and gels were analyzed by autoradiography, a strong band with apparent molecular weight of approximately 90 kDa was present in lysates of cells infected with the recombinant viruses but was absent in the lysates from wild-type infected cells. The presence of the chimeric $\text{F}_{\text{PIV-3}}-\text{F}_{\text{RSV}}$ protein in the lysates of cells infected with the recombinant baculoviruses was confirmed further by Western blot analysis using monospecific anti-PIV-3 F and anti-RSV F antisera and/or monoclonal antibodies (Mabs). Lysates from cells infected with the recombinant baculoviruses reacted with both anti-PIV-3 and anti-RSV antisera in immunoblots. As shown in the immunoblot of Figure 13, lysates from cells infected with either the RSV F or $\text{F}_{\text{PIV-3}}-\text{F}_{\text{RSV}}$ recombinant baculoviruses reacted positively with the anti-F RSV Mab. As expected, lysates from cells infected with wild type virus did not react.

with this Mab. In addition, only lysates from cells infected with the chimeric F_{PIV-3} - F_{RSV} recombinant viruses reacted with the anti-PIV-3 F₁ antiserum.

Example 8

5 This Example illustrates modification of the baculovirus transfer vector pVL1392 (obtained from Invitrogen), wherein the polyhedrin ATG start codon was converted to ATT and the sequence CCG was present downstream of the polyhedrin gene at positions +4,5,6.
10 Insertion of a structural gene several base pairs downstream from the ATT codon is known to enhance translation. The steps involved in constructing this modified baculovirus transfer vector are outlined in Figure 14.

15 The baculovirus expression vector pVL1392 was cut with EcoRV and BamHI. The 9.5 kb restricted pVL1392 vector was ligated to an EcoRV-BamHI oligonucleotide cassette (SEQ ID No: 15) to produce the pD2 vector.

Example 9:

20 This Example illustrates the construction of the pD2 baculovirus expression vector containing the chimeric F_{RSV} -HN_{PIV-3} gene consisting of the truncated RSV F and PIV-3 HN genes linked in tandem. The steps involved in constructing this plasmid are summarized in Figure 15.

25 To engineer the F_{RSV}-HN_{PIV-3} gene, the RSV F gene lacking the nucleotide sequence coding for the transmembrane domain and cytoplasmic tail of the RSV F glycoprotein was retrieved from plasmid pRSVF (Example 1) by cutting the polylinker with EcoRI and the gene with BspHI. The PIV-3 HN gene devoid of the DNA fragment coding for the hydrophobic anchor domain was retrieved from plasmid pPIVHN (Example 1) by cutting the gene with BspHI and the polylinker with BamHI. The 1.6 Kb EcoRI-BspHI RSV F gene fragment and the 1.7 Kb BspHI-BamHI PIV-3 HN gene fragment were isolated from low melting point agarose gels. For cloning purposes, the two BspHI sites

in the Bluescript based mammalian cell expression vector, pMCR20, were mutated. Mutations were introduced in the BspHI sites of the pMCR20 by cutting the expression vector with BspHI, treating both the BspHI restricted vector and the 1.1 Kb fragment released by the BspHI cut with Klenow polymerase and ligating the blunt-ended 1.1 Kb fragment to the blunt-ended Bluescript-based expression vector to generate plasmid pM'. Since insertion of the 1.1 Kb blunt-end fragment in the mammalian cell expression vector in the improper orientation would alter the Amp^r gene of the Bluescript-based expression vector, only colonies of HB101 cells transformed with the pM' plasmid DNA with the 1.1 Kb blunt-ended fragment in the proper orientation could survive in the presence of ampicillin. Plasmid DNA was purified from ampicillin-resistant colonies of HB101 cells transformed with plasmid PM' by equilibrium centrifugation in cesium chloride-ethidium bromide gradients. The 1.6 Kb EcoRI-BspHI RSV F and 1.7 Kb BspHI-BamHI PIV-3 HN gene fragments were directly cloned into the EcoRI-BamHI sites of vector pM' in a 3-way ligation to generate plasmid pM' RF-HN.

To restore specific coding sequences of the RSV F and PIV-3 HN genes removed by the BspHI cut, a BspHI-BspHI oligonucleotide cassette (SEQ ID No: 16) containing the pertinent RSV F and PIV-3 HN gene sequences was ligated via the BspHI site to the BspHI-restricted plasmid pM' RF-HN to produce plasmid pM RF-HN. Clones containing the BspHI-BspHI oligonucleotide cassette in the proper orientation were identified by sequence analysis of the oligonucleotide linker and its flanking regions.

To clone the chimeric F_{RSV}-HN_{PIV-3} gene into the baculovirus expression vector pD2 (Example 8), the F_{RSV}-HN_{PIV-3} truncated gene first was retrieved from plasmid pM RF-HN by cutting the plasmid with EcoRI. The 3.3 Kb F_{RSV}-

HN_{PIV-3} gene then was cloned into the EcoRI site of the baculovirus transfer vector plasmid pD2 to generate plasmid pD2 RF-HN (ATCC 75388). Proper orientation of the 3.3 Kb EcoRI F_{RSV}-HN_{PIV-3} chimeric gene insert in plasmid pD2 RF-HN was confirmed by sequence analysis.

Example 10:

This Example outlines the preparation of plaque-purified recombinant baculoviruses containing the chimeric F_{RSV}-HN_{PIV-3} gene.

10 Spodoptera frugiperda (Sf9) cells were co-transfected with 1 µg wild-type AcNPV DNA and 2 µg of F_{RSV}-HN_{PIV-3} plasmid DNA (plasmid pD2 RF-HN-Example 9). Putative recombinant baculoviruses (purified once by serial dilution) containing the F_{RSV}-HN_{PIV-3} chimeric gene 15 were identified by dot-blot hybridization. Lysates of insect cells infected with the putative recombinant baculoviruses were probed with the ³²P-labelled RSV F or PTV-3 HN gene oligonucleotide probes. Recombinant baculoviruses were plaque-purified three times before 20 being used for expression studies. All procedures were carried out according to the protocols outlined by Summers and Smith (Example 6).

Example 11:

This Example illustrates the presence of the 25 chimeric F_{RSV}-HN_{PIV-3} protein in supernatants of infected Sf9 and High 5 cells.

Insect cells (Sf9 and High 5), maintained in serum free medium EX401, were infected with the plaque purified recombinant baculoviruses of Example 10 at a m.o.i. of 5 30 to 10 pfu/cell. Supernatants from cells infected with the recombinant baculoviruses tested positive for expressed protein in both the RSV-F and PIV-3 HN specific ELISAS. In addition, supernatants from infected cells reacted positively with both an anti-F RSV monoclonal 35 antibody and anti-HN peptide antisera on immunoblots. A distinct band of approximately 105 kDa was present in the

immunoblots. These results confirm the secretion of the chimeric F_{RSV}-HN_{PIV-3} protein into the supernatant of Sf9 and High 5 cells infected with the recombinant baculoviruses.

5 Example 12:

This Example illustrates the purification of the chimeric F_{RSV}-HN_{PIV-3} protein from the supernatants of infected High 5 cells.

High 5 cells, maintained in serum free medium, were
10 infected with the plaque purified recombinant
baculoviruses of Example 10 at a m.o.i of 5 pfu/cell.
The supernatant from virus infected cells was harvested
2 days post-infection. The soluble F_{RSV}-HN_{PIV-3} chimeric
15 protein was purified from the supernatants of infected
cells by immunoaffinity chromatography using an anti-HN
PIV-3 monoclonal antibody. The anti-HN monoclonal
antibody was coupled to CNBr-activated Sepharose 4B by
conventional techniques. The immunoaffinity column was
washed with 10 bed volumes of washing buffer (10mM Tris-
20 HCl pH 7.5, 150 mM NaCl, 0.02% v/v Triton-X 100) prior to
use. After sample loading, the column was washed with 10
bed volumes of washing buffer followed by 3 bed volumes
of high salt buffer (10mm Tris-HCl pH 7.5, 500mM NaCl,
0.02% v/v Triton-X 100). The chimeric F_{RSV}-HN_{PIV-3} protein
25 was eluted from the immunoaffinity column with 100 MM
glycine, pH 2.5, in the presence of 0.02% Triton X-100.
Eluted protein was neutralized immediately with 1M Tris-
HCl, pH 10.7.

Polyacrylamide gel electrophoretic analysis (Fig.
30 16, panel A) of the immunoaffinity-purified F_{RSV}-HN_{PIV-3}
protein revealed the presence of one major protein band
with an apparent molecular weight of 105 kDa. The
purified protein reacted with both an anti-RSV F
monoclonal antibody and anti-HN peptide antisera on
35 immunoblots (Fig. 16, panel B, lanes 1 and 2,
respectively).

Example 13:

This Example illustrates the immunogenicity of the F_{RSV}-HN_{PIV-3} protein in guinea pigs.

Groups of four guinea pigs were injected
5 intramuscularly with either 1.0 or 10.0 µg of the
chimeric F_{RSV}-HN_{PIV-3} protein purified as described in
Example 12 and adjuvanted with aluminum phosphate.
Groups of control animals were immunized with either
placebo, or live PIV-3 or RSV (administered
10 intranasally). Guinea pigs were bled 2 and 4 weeks after
the primary injection and boosted at 4 weeks with an
equivalent dose of the antigen formulation. Serum
samples also were taken 2 and 4 weeks after the booster
dose. To assess the ability of the chimeric protein to
15 elicit PIV-3 and RSV-specific antibody responses, sera
samples were analyzed for the presence of PIV-3 specific
hemagglutination inhibiting and neutralizing antibodies
as well as RSV neutralizing antibodies. As summarized in
Table 1 below (the Tables appear at the end of the
20 disclosure), the sera of animals immunized with two 10 µg
doses of the chimeric protein had titres of PIV-3
specific hemagglutination inhibition (HAI) and PIV-3/RSV
neutralizing antibodies at the 6 and 8 week time points
which were equivalent to the levels obtained following
25 intranasal inoculation with either live PIV-3 or RSV. In
addition, animals immunized with only two 1 µg doses of
the chimeric protein elicited strong PIV-3 and RSV
specific neutralizing antibodies. These results
confirmed the immunogenicity of both the RSV and PIV-3
30 components of the chimeric protein and provided
confirmatory evidence that a single recombinant immunogen
can elicit neutralizing antibodies against both RSV and
PIV-3.

Example 14:

This Example illustrates the immunogenicity and protective ability of the F_{RSV}-HN_{PIV-3} protein in cotton rats.

Groups of eight cotton rats were injected 5 intramuscularly with either 1.0 or 10.0 ug of the chimeric F_{RSV}-HN_{PIV-3} protein (prepared as described in Example 12) adjuvanted with aluminum phosphate. Groups of control animals were immunized with either placebo (PBS + aluminum phosphate) or live PIV-3 or RSV 10 (administered intranasally). Cotton rats were bled 4 weeks after the primary injection and boosted at 4 weeks with an equivalent dose of the antigen formulation. Serum samples were also taken 1 week after the booster dose. As shown in Table 2 below, data from the 4-week 15 bleed demonstrated that both a 1 and 10 µg dose of the chimeric protein was capable of inducing a strong primary response. Reciprocal mean log₂ PIV-3 specific HAI and PIV-3/RSV neutralizing titers were equivalent to the titres obtained with live PIV-3 and RSV. Thus, a single 20 inoculation of the chimeric protein was sufficient to elicit neutralizing antibodies against both PIV-3 and RSV. Strong neutralizing PIV-3 and RSV titres also were observed following the booster dose (5 week bleed). These results provide additional evidence that both the 25 RSV and PIV-3 components of the chimeric protein are highly immunogenic.

To assess the ability of the chimeric immunogen to simultaneously protect animals against both RSV and PIV-3, four cotton rats from each group were challenged 30 intranasally with 100 TCID₅₀ units of either PIV-3 or RSV. Animals were killed 4 days after virus challenge. Virus titers were determined in lung homogenates. As shown in Table 3 below, animals immunized with either 1 or 10 µg 35 of the chimeric F_{RSV}-HN_{PIV-3} protein were completely protected against challenge with either PIV-3 or RSV. These results provide evidence that the chimeric protein

is not only highly immunogenic but can also simultaneously protect cotton rats against disease caused by both PIV-3 and RSV infection.

Example 15:

5 This Example illustrates the construction of a Bluescript M13-SK vector containing the chimeric F_{PIV-3} - G_{RSV} gene. This chimeric gene construct contains the 5' untranslated region of a mutated PIV-3 F gene but lacks the nucleotide sequence coding for the hydrophobic anchor
10 and cytoplasmic tail domains of both a mutated PIV-3 F and the native RSV G genes. The steps involved in constructing this plasmid are outlined in Figures 17 and 18.

The first step (Fig. 17) involved in preparing the
15 PIV-3 F component of the chimeric F_{PIV-3} - G_{RSV} gene construct was to eliminate the putative pre-termination sites within the 18 nucleotide long sequence 5' CAAGAAAAAGGAATAAAA 3' (SEQ ID No: 17) located between positions 857 and 874 of the non PCR-amplified PIV-3 F
20 gene and positions 847 and 864 of the PCR-amplified PIV-3 F gene (see Figure 1). To this end, the PIV-F cDNA of the non-PCR amplified PIV-3 F gene was cut at the BsaAI and EcoRI sites. The BsaAI-EcoRI PIV F gene fragment was cloned into the EcoRI site of a Bluescript M13-SK vector
25 using an EcoRI-BsaAI linker. The 857-874 target region of the PIV-3 F gene (non-PCR amplified) then was mutated by oligonucleotide-mediated mutagenesis using the method of Morinaga et al. [1984, Biotechnology 2: 636-639]. Plasmid pPI3Fc (Example 1) was cut with ScaI in the Amp' gene and dephosphorylated with alkaline phosphatase (plasmid #1). A second sample of plasmid pPI3Fc was cut with BstEII and NsiI to produce a 3.9 Kb restricted plasmid, lacking the 0.9 Kb BstEII-NsiI fragment of the PIV-3 F gene (plasmid #2). A mutagenic 78-mer synthetic
30 oligonucleotide (#2721 shown in Fig. 17-SEQ ID No: 18)) containing the sequence 5' CAGGAGAAGGGTATCAAG 3' (SEQ ID
35 No: 19) was annealed to the 3' end of the BstEII-NsiI fragment of plasmid #2 and used to transform E. coli JM109.

No: 19) was synthesized to specifically mutate the 857-874 DNA segment without changing the F protein sequence. This oligonucleotide was added to plasmid DNAs #1 and #2, denatured at 100°C for 3 min. and renatured by gradual cooling. The mixture then was incubated in the presence of DNA polymerase, dNTPs and T4 ligase and transformed into HB101 cells. Bacteria containing the 1.8 Kb mutated PIV-3 F gene were isolated on YT agar plates containing 100 µg/ml ampicillin. Hybridization with the oligonucleotide probe 5' AGGAGAAGGGTATCAAG 3' (SEQ ID No: 20) was used to confirm the presence of the mutated PIV-3 F gene. The mutated gene sequence was confirmed by DNA sequencing. The plasmid containing the mutated PIV-3 gene was designated pPI3Fm.

The second step (Fig. 18) in the engineering of the chimeric gene construct involved constructing a Bluescript based vector to contain the truncated PIV-3 Fm gene lacking the nucleotide sequence coding for the transmembrane anchor domain and cytoplasmic tail of the PIV-3 F protein linked in tandem with the RSV G gene lacking both the 5' leader sequence and the nucleotide sequence coding for the transmembrane anchor domain and cytoplasmic tail of the G glycoprotein.

To prepare this chimeric gene, the orientation of the mutated PIV-F gene in plasmid pPI3Fm first was reversed by EcoRI digestion and religation to generate plasmid pPI3Fmr. To prepare the PIV-3 F gene component of the chimeric gene, plasmid pPI3Fmr was cut with NotI and BsrI to release the 1.7 Kb truncated PIV-3 F gene. To prepare the RSV G component, the 0.95 Kb RSV-G gene lacking both the 5' leader sequence and the DNA segment encoding the G protein anchor domain and cytoplasmic tail was released from plasmid pRSVG (Example 1) by cutting the polylinker with EcoRI and the gene with BamHI. The 0.95 Kb EcoRI-BamHI RSV G gene fragment was subcloned into the EcoRI-BamHI sites of a restricted Bluescript

vector, pM13-SK, to produce plasmid pRSVGt. The 0.95 Kb EcoRI-BamHI G gene fragment and the 1.5 Kb NotI-BsrI truncated PIV-3 F gene were linked via a BsrI-BamHI oligonucleotide cassette (SEQ ID No: 9) restoring the F and G gene coding sequences and cloned into the pRSVGt vector restricted with BamHI and NotI in a 3-way ligation. The plasmid thus generated was designated pFG.

Example 16:

This Example outlines the construction of the pD2 baculovirus transfer vector (described in Example 8) containing the chimeric $F_{PIV-3}-G_{RSV}$ gene consisting of a mutated PIV-3 F gene lacking the hydrophobic anchor and cytoplasmic coding regions linked to the RSV G gene lacking both the 5' leader sequence and the nucleotide sequences encoding the transmembrane anchor domain and cytoplasmic tail of the G protein.

To prepare this construct, plasmid pFG (Example 15) was cut with EcoRI to release the 2.6 Kb $F_{PIV-3}-G_{RSV}$ chimeric gene. The 2.6 Kb EcoRI restricted chimeric gene fragment then was sub-cloned into the EcoRI site of the dephosphorylated pD2 vector to generate the 12.1 Kb plasmid pD2F-G (ATCC 75389).

Example 17:

This Example outlines the preparation of plaque-purified recombinant baculoviruses containing the chimeric $F_{PIV-3}-G_{RSV}$ gene.

Spodoptera frugiperda (Sf9) cells were co-transfected with 2 ug of pD2F-G plasmid DNA (Example 16) and 1 ug of linear wild-type AcNPV DNA (obtained from Invitrogen). Recombinant baculoviruses containing the $F_{PIV-3}-G_{RSV}$ gene were plaque-purified twice according to the procedure outlined in Example 10.

Example 18:

This Example illustrates the presence of the chimeric $F_{PIV-3}-G_{RSV}$ protein in the supernatant of Sf9 and High 5 cells infected with the recombinant baculoviruses.

Sf9 and High 5 cells were infected with recombinant baculoviruses containing the F_{PIV-3}-G_{RSV} gene (Example 16) at a m.o.i. of 5 to 10 pfu/cell. The supernatant of cells infected with the recombinant viruses tested 5 positive for expressed protein in the PIV-3 F specific ELISA. Supernatants of infected cells reacted with both anti-F PIV-3 and anti-G RSV monoclonal antibodies in immunoblots. These results confirm the presence of the chimeric F_{PIV-3}-G_{RSV} protein in the supernatants of infected 10 Sf9 and High 5 cells.

Example 19:

This Example outlines the preparation of recombinant vaccinia viruses expressing the F_{PIV-3} - F_{RSV} and F_{RSV} - HN_{PIV-3} genes.

Vaccinia virus recombinant viruses expressing the 15 F_{PIV-3}-F_{RSV} (designated vP1192) and F_{RSV}-HN_{PIV-3} (designated vP1195) genes were produced at Virogenetics Corporation (Troy, NY) (an entity related to assignee hereof) using the COPAK host-range selection system. Insertion 20 plasmids used in the COPAK host-range selection system contained the vaccinia K1L host-range gene [Perkus et al., (1990) *Virology* 179:276-286] and the modified vaccinia H6 promoter [Perkus et al. (1989), *J. Virology* 63:3829-3836]. In these insertion plasmids, the K1L 25 gene, H6 promoter and polylinker region are situated between Copenhagen strain vaccinia flanking arms replacing the ATI region [open reading frames (ORFs) A25L, A26L; Goebel et al., (1990), *Virology* 179: 247-266; 517-563]. COPAK insertion plasmids are designed for use 30 in in vivo recombination using the rescue virus NYVAC (vP866) (Tartaglia et al., (1992) *Virology* 188: 217-232). Selection of recombinant viruses was done on rabbit kidney cells.

Recombinant viruses, vP1192 and vP1195 were 35 generated using insertion plasmids pES229A-6 and PSD.RN, respectively. To prepare plasmid pES229A-6 containing

the $F_{PIV.3}-F_{RSV}$ gene, the COPAK-H6 insertion plasmid pSD555 was cut with SmaI and dephosphorylated with intestinal alkaline phosphatase. The 2.6 Kb $F_{PIV.3}-F_{RSV}$ gene was retrieved from plasmid pES60A (Example 4) by cutting the 5 plasmid with EcoRI and BamHI. The 2.6 Kb EcoRI-BamHI $F_{PIV.3}-F_{RSV}$ gene was blunt ended with Klenow polymerase, isolated from a low melting point agarose gel and cloned into the SmaI site of the COPAK-H6 insertion plasmid pSD555 to generate plasmid pES229A-6. This positioned 10 the $F_{PIV.3}-F_{RSV}$ ORF such that the 5' end is nearest the H6 promoter.

To prepare plasmid PSD.RN, the pSD555 vector first was cut with SmaI and BamHI. Plasmid pM RF-HN (Example 9) containing the truncated $F_{RSV}-HN_{PIV.3}$ gene was cut with 15 ClaI, blunt ended with Klenow polymerase and then cut with BamHI. The 3.3 Kb $F_{RSV}-HN_{PIV.3}$ gene was cloned into the SmaI-BamHI sites of the pSD555 vector to generate plasmid PSD.RN. This positioned the $F_{RSV}-HN_{PIV.3}$ ORF such that the H6 5' end is nearest the H6 promoter.

20 Plasmids pES229A-6 and PSD.RN were used in in vitro recombination experiments in vero cells with NYVAC (vP866) as the rescuing virus. Recombinant progeny virus was selected on rabbit kidney (RK)-13 cells (ATCC #CCL37). Several plaques were passaged two times 25 on RK-13 cells. Virus containing the chimeric genes were confirmed by standard *in situ* plaque hybridization [Piccini et al. (1987), Methods in Enzymology, 153:545-563] using radiolabeled probes specific for the PIV and RSV inserted DNA sequences. Plaque purified virus 30 containing the $F_{PIV.3}-F_{RSV}$ and $F_{RSV}-HN_{PIV.3}$ chimeric genes were designated vP1192 and vP1195, respectively.

Radioimmunoprecipitation was done to confirm the expression of the chimeric genes in vP1192 and vP1195 infected cells. These assays were performed with lysates 35 prepared from infected Vero cells [according to the procedure of Taylor et al., (1990) J. Virology 64, 1441-

1450] using guinea pig monospecific PIV-3 anti-HN and
anti-F antiserum and rabbit anti-RSV F antiserum. Both
the anti-PIV F and anti-RSV F antisera precipitated a
protein with an apparent molecular weight of
5 approximately 90 kDa from vP1192 infected Vero cells.
Both anti-RSV F and guinea pig anti-PIV HN antisera
precipitated a protein with an apparent molecular weight
of approximately 100 kDa from vP1195 infected cells.
These results confirmed the production of the $F_{PIV-3}-F_{RSV}$
10 and $F_{RSV}-HN_{PIV-3}$ chimeric proteins in Vero cells infected
with the recombinant poxviruses.

SUMMARY OF DISCLOSURE

In summary of the disclosure, the present invention
provides multimeric hybrid genes which produce chimeric
15 proteins capable of eliciting protection against
infection by a plurality of pathogens, particularly PIV
and RSV. Modifications are possible within the scope of
this invention.

Table 1 Secondary antibody response of guinea pigs immunized with the chimeric F_{RSV}-HNPIV-3 protein

Antigen Formulation	Dose (ug)	HAI Titre ^a (log ₂ ± s.e.)		Neutralization Titre ^b (log ₂ ± s.e.)		
		PIV-3		RSV		
		6 wk Bleed	8 wk Bleed	6 wk Bleed	8 wk Bleed	6 wk Bleed
Buffer	-	<1.0 ± 0.0	<1.0 ± 0.0	<1.0 ± 0.0	<1.0 ± 0.0	<1.0 ± 0.0
F _{RSV} -HNPIV-3	10.0	9.1 ± 0.3	9.1 ± 0.3	7.1 ± 0.3	7.1 ± 0.5	5.5 ± 0.9
	1.0	7.0 ± 2.0	7.3 ± 2.2	5.0 ± 1.5	4.5 ± 1.4	4.5 ± 0.5
Live PIV-3		8.6 ± 0.7	7.3 ± 0.6	7.0 ± 0.4	7.3 ± 0.6	N/A
Live RSV		N/A ^c	N/A	N/A	N/A	5.5 ± 1.5
						5.0 ± 1.0

^a Reciprocal mean log₂ serum dilution which inhibits erythrocyte agglutination by 4 hemagglutinating units of PIV-3

^b Reciprocal mean log₂ serum dilution which blocks hemadsorption of 100 TCID₅₀ units of PIV-3 or RSV

^c N/A - not applicable

Table 2: serum antibody response of cotton rats immunized with the chimeric F_{RSV}-HN_{PIV-3} protein^a

Antigen Formulation	Dose (ug)	HAI Titre ^b ($\log_2 \pm$ s.d.)		Neutralization Titre ^c ($\log_2 \pm$ s.d.)				RSV
		PIV-3	RSV	4 wk Bleed	5 wk Bleed	4 wk Bleed	5 wk Bleed	
Buffer	-	2.8 ± 0.5	<3.0 ± 0.0	<1.0 ± 1.0	<1.0 ± 0.0	1.8 ± 0.3	0.8 ± 0.7	
F _{RSV} -HN _{PIV-3}	10.0	9.5 ± 1.3	10.5 ± 0.6	>9.0 ± 0.0	>9.0 ± 0.0	5.2 ± 1.1	5.8 ± 0.9	
	1.0	9.3 ± 1.0	10.3 ± 0.5	>9.0 ± 0.0	>9.0 ± 0.0	5.0 ± 0.7	5.8 ± 1.2	
Live PIV-3		7.0 ± 0.0	8.5 ± 0.7	>9.0 ± 0.0	9.2 ± 0.7	N/A	N/A	
Live RSV		N/A ^d	N/A	N/A	N/A	5.5 ± 0.6	8.5 ± 0.6	

^a Each value represents the mean titre of antisera from 8 animals.

^b Reciprocal mean log₂ serum dilution which inhibits erythrocyte agglutination by 4 hemagglutinating units of PIV-3

^c Reciprocal mean log₂ serum dilution which blocks hemadsorption of 100 TCID₅₀ units of PIV-3 or RSV

^d N/A - not applicable

Table 3. Response of immunized cotton rats to PIV/RSV challenge^a

Antigen Formulation	Dose (ug)	Mean virus lung titre \log_{10}/g lung \pm s.d.	
		RSV	PIV-3
Buffer	-	3.7 \pm 0.3	3.4 \pm 0.3
F _{RSV-HN} _{PIV-3}	10.0	\leq 1.5 \pm 0.0	\leq 1.5 \pm 0.0
F _{RSV-HN} _{PIV-3}	1.0	\leq 1.5 \pm 0.0	\leq 1.5 \pm 0.0
Live RSV		\leq 1.5 \pm 0.0	\leq 1.5 \pm 0.0
Live PIV-3		\leq 1.5 \pm 0.0	\leq 1.5 \pm 0.0

^a Animals were challenged intranasally with 100 TCID₅₀ units of PIV-3 or RSV and killed 4 days later. Each value represents the mean virus lung titre of 4 animals.

CLAIMS

What we claim is:

1. A multimeric hybrid gene, comprising a gene sequence coding for an antigenic region of a protein from a first pathogen linked to a gene sequence coding for an antigenic region of a protein from a second pathogen.
2. The hybrid gene of claim 1 wherein said first and second pathogens are selected from bacterial and viral pathogens.
3. The hybrid gene of claim 2 wherein both said first and second pathogens are viral pathogens.
4. The hybrid gene of claim 1 wherein said first and second pathogens are selected from those causing different respiratory tract diseases.
5. The hybrid gene of claim 4 wherein said first and second pathogens causing different respiratory tract diseases are selected from the paramoxyviridae family of viruses.
6. The hybrid gene of claim 1 wherein at least one of said gene sequences is mutated while retaining antigenicity.
7. The hybrid gene of claim 6 wherein said mutation is at a putative pre-termination site.
8. The hybrid gene of claim 1 wherein said first pathogen is parainfluenza virus (PIV) and said second pathogen is respiratory syncytial virus (RSV).
9. The hybrid gene of claim 1, comprising at least one gene sequence coding for a parainfluenza virus (PIV) protein linked to at least one gene sequence coding for a respiratory syncytial virus (RSV) protein.
10. The hybrid gene of claim 9, wherein said parainfluenza virus protein is selected from PIV-3 F and HN proteins and said respiratory syncytial virus protein is selected from RSV G and F proteins.
11. The hybrid gene of claim 1 consisting of a gene sequence coding for a human PIV-3 F or HN protein or an

immunogenic epitope-containing fragment thereof linked to a gene sequence coding for a human RSV G or F protein or an immunogenic epitope-containing fragment thereof.

12. The hybrid gene of claim 11 which is selected from $F_{PIV-3} - F_{RSV}$, $F_{RSV} - HN_{PIV-3}$ and $F_{PIV-3} - G_{RSV}$ hybrid genes.

13. The hybrid gene of claim 1 contained in an expression vector.

14. The hybrid gene of claim 13 in the form of plasmid pAC DR7, pD2 RF-HN or pD2 F-G.

15. The hybrid gene of claim 1 further comprising at least one gene encoding at least one immunogenic and/or immunostimulating molecule.

16. Cells containing the multimeric hybrid gene of claim 1 for expression of a chimeric protein encoded by said gene.

17. The cells of claim 16 which are bacterial cells, mammalian cells, insect cells, yeast cells or fungal cells.

18. A chimeric protein, comprising an antigenic region of a protein from a first pathogen linked to an antigenic region of a protein from a second pathogen.

19. The protein of claim 18, wherein said first and second pathogens are selected from bacterial and viral pathogens.

20. The protein of claim 19 wherein both said first and second pathogens are viral pathogens.

21. The protein of claim 18, wherein said first and second pathogens are selected from those causing different respiratory tract diseases.

22. The protein of claim 21 wherein said first and second pathogens causing different respiratory tract diseases are selected from the paramoxyviridae family of viruses.

23. The protein of claim 18, wherein said first pathogen is parainfluenza virus (PIV) and said second pathogen is respiratory syncytial virus (RSV).

24. The protein of claim 18 comprising at least one parainfluenza virus (PIV) protein linked to at least one respiratory syncytial virus (RSV) protein.

25. The protein of claim 24, wherein said PIV protein is selected from PIV-3 F and HN proteins and said RSV protein is selected from RSV G and F proteins.

26. The protein of claim 18 consisting of a human parainfluenza virus-3 (PIV-3) F or HN protein or an immunogenic epitope-containing fragment thereof linked to a human respiratory syncytial virus (RSV) G or F protein or an immunogenic epitope-containing fragment thereof.

27. The protein of claim 26 which is selected from $F_{PIV-3} - F_{RSV}$, $F_{RSV} - HN_{PIV-3}$ and $F_{PIV-3} - G_{RSV}$ chimeric proteins.

28. A process for preparation of a chimeric protein which comprises:

isolating a gene sequence coding for an antigenic region of a protein from a first pathogen,

isolating a gene sequence coding for an antigenic region of a protein from a second pathogen,

linking said gene sequences to form a multimeric hybrid gene, and expressing the multimeric hybrid gene in a cellular expression system

29. The process of claim 28 wherein said multimeric hybrid gene comprises a gene sequence coding for a PIV-F or HN protein or an immunogenic epitope-containing fragment thereof linked to a gene sequence coding for a human RSV G or F protein or an epitope-containing fragment thereof.

30. The process of claim 29 wherein said multimeric hybrid gene is selected from $F_{PIV-3} - F_{RSV}$, $F_{RSV} - HN_{PIV-3}$ and $F_{PIV-3} - G_{RSV}$ hybrid genes.

31. The process of claim 30 wherein said multimeric hybrid gene is contained in an expression vector comprising plasmid pAC QR7, pD2 RF-HN or pD2 F-G.

32. The process of claim 28 wherein said cellular expression system is provided by bacterial cells,

mammalian cells, insect cells, yeast cells or fungal cells.

33. The process of claim 32 including separating a chimeric protein from a culture of said cellular expression system and purifying the separated chimeric protein.

34. A live vector for antigen delivery containing the gene of claim 1.

35. The live vector of claim 34 which is a viral vector.

36. The live vector of claim 35 wherein said viral vector is selected from poxviral, adenoviral and retroviral viral vectors.

37. The live vector of claim 34 which is a bacterial vector.

38. The live vector of claim 37 wherein said bacterial vector is selected from salmonella and mycobacteria.

39. A vaccine against diseases caused by multiple pathogenic infections, comprising a chimeric protein comprising an antigen region of a protein from a first pathogen linked to an antigenic region of a protein from a second pathogen, and a physiologically-acceptable carrier therefor.

40. The vaccine of claim 39, wherein said first and second pathogens are selected from bacterial and viral pathogens.

41. The vaccine of claim 39, which also contains at least one other immunogenic and/or immunostimulating molecule.

42. The vaccine of claim 40 wherein both said first and second pathogens are viral pathogens.

43. The vaccine of claim 39, wherein said first and second pathogens are selected from those causing upper and lower respiratory tract diseases.

44. The vaccine of claim 39, wherein said first pathogen is parainfluenza virus (PIV) and said second pathogen is respiratory syncytial virus (RSV).

45. The vaccine of claim 39 against infection by both parainfluenza virus (PIV) and respiratory syncytial virus (RSV), comprising a recombinant multimeric protein containing at least one segment consisting of a PIV protein or an immunogenic epitope-containing fragment thereof linked to at least one segment consisting of a RSV protein or an immunogenic epitope-containing fragment thereof, and a carrier therefor.

46. The vaccine of claim 45 wherein said recombinant multimeric protein is a recombinant chimeric protein containing a segment consisting of a PIV-3 F or HN protein or an immunogenic epitope-containing fragment thereof linked to a segment consisting of an RSV G or F protein or an immunogenic epitope-containing fragment thereof.

47. The vaccine of claim 46 containing at least one additional protein of PIV or RSV or chimeric protein thereof.

48. The vaccine of claim 39 wherein said carrier comprises an adjuvant.

49. The vaccine of claim 39 wherein said carrier is an ISCOM, a liposome or a microparticle.

50. The vaccine of claim 46 formulated to be administered in an injectable form, intranasally or orally.

51. The vaccine of claim 39 further comprising means for delivering said multimeric protein specifically to cells of the immune system.

52. The vaccine of claim 51 wherein said delivery means comprises a toxin molecule or an antibody.

53. A vaccine against diseases caused by multiple pathogenic infection, comprising a live vector as claimed in claim 34, and a physiologically-acceptable carrier therefor.

54. A method of immunizing a host against diseases caused by multiple pathogenic infections, which comprises

administering to a host an effective amount of a vaccine as claimed in claim 28 or 53.

55. The method of claim 54 wherein said vaccine is against diseases caused by parainfluenza virus (PIV) and respiratory syncytial virus (RSV).

56. The method of claim 55 wherein said host is selected from infants, young children, pregnant women, women of child-bearing age and susceptible persons.

57. A diagnostic reagent for detecting infection by a plurality of different pathogens in a host, comprising the chimeric protein claimed in claim 18.

58. A method of detecting infection by a plurality of different pathogens in a host, which comprises using said chimeric protein claimed in claim 18.

FIG.1A. NUCLEOTIDE SEQUENCE OF THE PIV-3 F GENE (PCR-AMPLIFIED)

AAGTCAATAACCAACTATTAGCAGTCATACTGCAAGAACAAAGAAGAAAGATTCAA
TTCAAGTTATGGTTGTATAATCGTCAAGTATGCACTTCTTCTCTTAAGTT
10 20 30 40 50 60

AAAAGCTAAATAAGAGAAATCAAAACAAAGGTATAGAACCCGAAACACCCAAATCAAA
TTTCGATTATCTCTTTAGTTTGGCATATCTTGTGGCTTGTGTTAGTTTGGTTT
70 80 90 100 110 120

CATCCAACTTAAACAAAAATTCCAAAAGGACCGGCAACACAAAGCACC
 GTAGGTTAGGTAAATTGTTAAGTTT140
 130 140 150 160 170 180
 MET PRO THR [LEU] ILE LEU ILE THR THR MET ALA [SER] SER CYS GLN
 ACCAATGCCAACCTTAATACTGCTTAACTATTACAACTTACATTGATTATGGCATCTTCCCTGCCAA
 TGGTACGGTTGAATATGACGATTAAATAATGTTACTAAATACCGTAGAAGGGACGGTT
 190 200 210 220 230 240

ILE ASP ILE THR LYS LEU GLN HIS VAL GLY VAL LEU VAL ASN SER PRO LYS GLY MET LYS
 ATACATACTACAAACTACAGCATGTAAGGTGTTGGTCAACAGTCCCACAGGATGGATGAAG
 TATGTTAGTGTTGATGTCGATCACATCCACATAACCAGTTGTCAGGGTTCCCTACTTC
 250 260 270 280 290 300

ILE SER GLN ASN PHE GLU THR ARG TYR LEU ILE LEU SER LEU ILE PRO LYS ILE GLU ASP
 ATATCACAACCTTCGAACAAAGATACTTAATTGAGCTCATACCAAAAATAGAAGAC
 TATAGTGTGAAACTTTCTATAGATTAAACTCGGAGATGGTTATCTTCTG
 310 320 330 340 350 360

SER ASN SER CYS GLY ASP GLN GLN ILE LYS GLN TYR LYS ARG LEU LEU ASP ARG LEU ILE
 TCTTAAC TCTTGTTGACCAACAGATCAAACAAATAACAGGGTTATGGATAAGCTGATC
 AGATTGAAACACCCTGGTCTAGTTATGTTACCTATCTGACTAG
 370 380 390 400 410 420

F2-FL CLEAVAGE SITE

ASN	GLU	ASN	THR	ASP	PRO	ARG	THR	[ARG]	[SER]	PHE	GLY	GLY	VAL	ILE	GLY	THR	ILE	ALA
AAT	GAA	AAC	ACT	GAT	CCC	AGA	ACA	AAG	CAT	TCT	GAG	GGG	GTAA	TGG	AAACC	TTTGCT		
T	T	A	C	T	T	T	T	T	T	T	T	T	T	T	C	C	C	A
TA	ACT	TTT	GTG	ACT	TTT	GTG	ACT	TTT	GTG	CTT	GCA	TGG	CTG	TCT	GGT	CC	TT	AA
490	500	510	520	530	540	550	560	570	580	590	600	610	620	630	640	650	660	670

LEU GLY VAL ALA THR SER ALA GLN ILE THR ALA ALA VAL ALA LEU VAL GLU ALA LYS GLN
 CTGGGA GTAGCCAACCTCA GACAATTACAGGCCAGTTGCTCTGGTGTGAGTCGGTCAACGAGACAACTTCGGTTCGTC
 GACCCCATGGCTGGAGTTGGATTAATGTCGGTCAACGAGACAACTTCGGTTCGTC
 550 560 570 580 590 600

SER VAL GLN SER SER ILE GLY ASN LEU ILE VAL ALA ILE LYS SER VAL GLN ASP TYR VAL
TCAGTTCAAGCTCTATAGGAATTTAAATTAGTAGGAAATTAAATCAGTCCAAAGATTAAATGTC
AGTCAAAGTCTGAGATACTCTAAATTATCATGGTTAAATTAGTCAAGGTCTTAATACAG
670 680 690 700 710 720

ASN [ASN] GLU ILE VAL PRO SER ILE ALA ARG LEU GLY CYS GLU ALA ALA GLY LEU GLN LEU
ACAAAGGAATCGTGCATCGATTGCTAGACTAGGTTGTGAAGCAGGACTTCATTAA
TTGGCTTAGCAGGTAACGATCTGATCCACACTTGTGTCCTGAAATTAA
750 770 770 780
730 740 750 760

GLY ILE ALA LEU THR GLN HIS TYR SER GLU LEU THR ASN ILE PHE GLY ASP ASN ILE GLY
 GGAAATTGCAATTAAACAGGATTAACAGGATTACCTCAGAAATACATTGGTGAATTAACAAACATAATTGGTGAATTTGTTAAACCACTATTGTATCCT
 CCTTAACCGTAATTGGTGTGGTAAATGAGTCCTTAATTTGTTAAACCACTATTGTATCCT 840
 790 800 810 820 830 840

FIG. IC. SER LEU GLN GLU LYS GLY ILE LYS LEU GLN GLY ILE ALA SER LEU TYR ARG THR ASN ILE
 TCGTTACAAGAAAAATTACAAAGGTATAGCATCATTATACCCACAAATACT
 AGCAATTTCTTCTTAAATTAAATGTTCCATATCGTAGTAATGGCGTTTATAAG
 850 870 880 890 900

THR GLU ILE PHE THR THR SER THR VAL ASP LYS TYR ASP ILE TYR ASP LEU LEU PHE THR
 ACAAGAAATTTCACACATCAACAGTTGATAAAATGATATCTATGATCTATTACCA
 TGTCTTAAAGTGTAGTGTAGTGTAGTGTAGTGTAGTGTAGTGTAGTGTAGTGTAGT
 910 930 940 950 960

GLU SER ILE LYS VAL ARG VAL ILE ASP VAL ASP LEU ASN ASP TYR SER ILE THR LEU GLN
 GAAATCAAAGGTAGAGTTATAGATGTTGATTGATTTGAAATGATTACTCAATCACCCCAA
 CTAGTATTTCACCTCAATCTACAAACTAAACTAAACTAAACTAAACTAAACTAAACTAA
 970 980 990 1000

VAL ARG LEU PRO LEU LEU THR ARG LEU LEU ASN THR GLN ILE TYR **[LYS]** VAL ASP SER ILE
 GTCAAGACTCCCTTAACTAGGCTTGTGAACACTCAAGATCTACAAAGTAGATTCCATA
 CAGTCTGAGGGAATAATTGATCCGACCACTTACCATAGGGAGAAAGGGTATAAGGTAT
 1030 1040 1050 1060 1070

SER TYR ASN ILE GLN ASN ARG GLU TRP TYR ILE PRO LEU PRO SER HIS ILE MET THR LYS
 TCATATAATTCAAAACAGAGAAATGGTATATCCCTTCCAGCCATATCATGAGAAA
 AGTATAATTAGTTTGTCTCTACCATAGGGAGAAAGGGTATAAGTACTGCTT
 1090 1100 1110 1120 1130

GLY ALA PHE LEU GLY ALA ASP VAL LYS GLU CYS ILE GLU ALA PHE SER SER TYR ILE
 GGGCATTCTAGTTGGAGCAGATGTCAAGGAAATGTATAGAACCTTCAAGCAGTTATA
 CCCGTTAAAGATCCACCTCGTCTACATATCTCGTAAGTCGTTACATATA
 1150 1160 1170 1180 1190

CYS PRO SER ASP PRO GLY PHE VAL LEU ASN HIS GLU KET GLU SER CYS LEU SER GLY ASN
 TGCCTCTCTGATCCAGGATTGTACTAAACCATGAAATGGAGAGCTGTCTATCAGGAAAC
 ACGGGAAGACTAGGTCTAACATGATTGGTACTTACCTCTGACGAATAGTCTTG
 1220 1230 1240 1250 1260

3/39

5/39

E.G.E.

MET ILE ILE LEU PHE ILE ILE ASN VAL THR ILE ILE [THR] ILE ALA [ILE] LYS TYR TYR
 ATGATCATTATTTGTTTAAATTAAAGGATAATTGTAACCTAAATTACATTGGCAATTAAAGTATTACATTAACTTAACTTAAATTCAATAATG
 TACTAGTAAATAACAAATAATTAACTTACATTGGCTTAAATTGTTAACGTTAACTTAACTTAAATTCAATAATG
 1690 1700 1710 1720 1730 1740
 ARG ILE GLN LYS ARG ASN ARG VAL ASN ASP GLN ASN ASP PRO TYR VAL LEU THR ASN LYS
 AGAATTCAAAGAGAAATCGAGTGGATCAAATGACAAGCCATAATGACTAAACAAACAAA
 TCTTAAGTTCTCTTAGCTTACCTAGTTTACTGTTACATGATTGTTACATGATTGTTGTT
 1750 1760 1770 1780 1790 1800
 TGACATATCATTAGATCATTAGATATTAAATTAAAAAAACTT
 ACTGTATAGATATCTAGTAATCTATAATTAAATTATTTTGAA
 1820 1830 1840
 1850

SUBSTITUTE SHEET

6/39

RESTRICTION MAP OF THE PIV-3 F GENE




FIG.2.

FIG. 3A: NUCLEOTIDE SEQUENCE OF THE PIV-3 HN GENE.

THR GLN GLN MET SER ASP LEU ARG LYS PHE ILE SER GLU ILE THR ILE ARG ASN ASN
 GACACAACAGATTCAGATTCTAGGAAATTCTTACAGTCTAGAATCCTTTAGTAACTTACCTTAATGTTACTATT
 CTGTGTTCTACAGTCTAGAATCCTTTAGTAACTTACCTTAATGTTACTATTACCTTAATGTTACTATT
 370 380 390 400 410 420
[GLN] GLU VAL **[LEU]** PRO GLN ARG ILE THR HIS ASP **[VAL]** GLY ILE LYS PRO LEU ASN PRO ASP
 TCAAGAAGTGGCTGCCAACAAAGATAACACATGATGTTGGTATTAACCTTAAATCCAGA
 AGTTCTCACCGAACGGTCTTCTTACTACACTACACCCATATTGGAAATTAGGTCT
 430 440 450 460 470 480
 ASP PHE TRP ARG CYS THR SER GLY LEU PRO SER LEU MET LYS THR PRO LYS ILE ARG LEU
 TGATTTTGAGATGGCACGGTCTTCATCTTAAATGAAAACCTCCAAACAAATTAAGGTT
 ACTAAAAACCTTACGTTGAGGTTAGAAATTACTTTGAGGTCTTATTCCAA
 490 500 510 520 530 540
 MET PRO GLY PRO GLY LEU LEU ALA MET PRO THR THR VAL ASP GLY CYS **[ILE]** ARG THR PRO ⁸⁸
 ATGCCAGGGGGGATTTAGCTATGCCAACGACTGTTGGCTGTATGAGCTCC
 TTACGGTCCCCGGCTAAATCGATAACGGTACGAACTACCCGACATAGTTGAGG
 550 560 570 580 590 600
 SER LEU VAL ILE ASN ASP LEU ILE TYR THR SER ASN LEU ILE THR ARG GLY CYS
 GTCCTAGTATAATGATCTGATTATGCTTACCTCAAATCTAAATTACTCAGGGTTG
 CAGGAATCAATTACAGCTAAATGAGTTAGATTGAGTTAGATTGAGCTCCAAAC
 610 620 630 640 650 660
 GLN ASP ILE GLY LYS SER TYR GLN VAL LEU GLN ILE GLY* ILE THR VAL ASN SER ASP
 TCAAGGATATAGGAAATCATACAGTCTTACAGATAAGGATAATAACTGTTAAACTCAGA
 AGTCCCTATCCTTTAGTATAGTTAGAATGTTAGAATGTTCTTACCTTATTGACATTGAGCT
 670 680 690 700 710 720
 LEU VAL PRO ASP LEU ASN PRO ARG ILE SER HIS THR PHE ASN ILE ASN ARG LYS
 CCTGGTACCTGACTTAATCCAGGATCTCTCATTTACATTAGGTTCTTACATTGAGTAAATGAAATCTCTTACCTTACTCTT
 GAACCATGGACTGAAATTAGGTTCTTACATTGAGTAAATGAAATCTCTTACATTGAGTAAATGAAATCTCTTACCTTACTCTT
 730 740 750 760 770 780

SRE CYS SER LEU ALA LEU LEU ASN THR ASP VAL TYR GLN LEU CYS SER THR PRO LYS VAL
 GTCATGTTCTAGCACCTAAATACAGGATTTGAGGATTGGTCAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGT
 CAGTACAAGAGATCGTGGAT 840
 800 820 840

ASP GLU ARG SER ASP TYR ALA SER SER GLY ILE GLU ASP ILE VAL LEU ASP ILE VAL ASN
 TGTATGAAAGATCAGATTAGCATTCAGGCATAGAAAGATAATTGACTTACATTTGATTTGATTTGATTTGCTAA
 ACTACCTTCTAGTCTTAATACGGTAGTAGTACCTTACAGTAACTTACATGAACTAACATGAACTAACAGT
 850 860 880 900

[TYR] ASP GLY SER ILE SER THR THR ARG PHE LYS ASN ASN ILE SER PHE ASP GLN PRO
 TTATGATGGCTCAATCTCAACAAACAAAGATTAAAGAAATAACATAAGCTTGGATCAACC
 AATACATACCGAGATTAGAGTTAGTTCTAAATTCTTATTATGTATTGTTGG
 910 920 930 940 950 960

TYR ALA ALA LEU TYR PRO SER VAL GLY PRO GLY ILE TYR TYR LYS GLY LYS ILE ILE PHE
 TTATGCTGGACTTACCCATCTGGACCAAGGATATACTACACAAAGGGAAATAAAATT
 AATACGACCTGGTATGGTAGACAACTGGTCCCTATGGT
 970 980 990 1000 1010 1020

LEU GLY TYR GLY LEU GLU HIS PRO ILE ASN GLU ASN **[VAL]** ILE CYS ASN THR THR GLY
 TCTCGGGTATGGAGGTCTTGAACATCCAAATGAGAATGTAATCTGCAACACAACACTGG
 AGAGCCCATACCTCCAGAACCTCTGGTTAGTTACTTACCTTACATTAGCCTTGGT
 1030 1040 1050 1060 1070 1080

CYS PRO GLY LYS THR GLN ARG ASP CYS ASN GLN ALA SER HIS SER PRO TRP PHE SER ASP
 GTGTCGGGGAAACACAGAGAGACTGGCATGGCATCTGCAACACTGGTTGGT
 CACAGGGCCCTTTGTTCTGACGTAGTCCGGTAGAGTATCAGGT
 1090 1100 1110 1120 1130 1140

ARG ARG MET VAL ASN SER ILE ILE VAL VAL ASP LYS GLY LEU ASN SER ILE PRO LYS LEU
 TAGGAGGATGGTCAACTCTATCATTTGATTTGACAAAGGGCTTAAACTCAATTCCAAATT
 ATCCCTACCAAGTTGAGATAGTAACAAACAAACTGTTCCGAAATTGAGTTAAGGGTTTAA
 1150 1160 1170 1180 1190 1200

LYS VAL TRP THR ILE SER MET ARG GLN ASN TYR TRP GLY SER GLU GLY ARG LEU LEU
 GAGGATGGACCATATGAGACAGATTACTGGGGTCAAGAAGGAAAGGTACTTCT
 CTTCCATACCTGGCTATAGATACCTGCTTAATGACCAGTCCTCCATGAAAGA
 1220 1230 1240 1250 1260

LEU GLY ASN LYS ILE TYR ILE TYR THR ARG SER THR SER HIS SER LYS LEU GLN LEU
 ACTAGGTAACAAAGATCTTATATAACAAGATCACAGTGGCATAGCAAGTTACAAATT
 T GATCCATTGTTCTAGATATATGTTCTAGATATGTTCAACCGTATCGTTCAATGTTAA
 1270 1280 1290 1300 1310 1320

GLY ILE ILE ASP ILE THR ASP TYR SER ASP ILE ARG ILE LYS TRP THR HIS ASN VAL
 AGGAATAATTGATATTACTGATTACAGTGATATAAGGATAAAATGGACATGGCATAATGTT
 T CCTTAACTTAACTATAATGACTATGTTCACTATGTTCACTATGTTCACTTACAA
 1330 1340 1350 1360 1370 1380

LEU SER ARG PRO GLY ASN ASN GLU CYS PRO TRP GLY HIS SER CYS PRO ASP GLY CYS ILE
 GCTATCAAGACCAGGAAACAAATGAAATGCAATGCTTACCTTACAGGTACCCCTGTTAAAGTACAGGTTACCTACATA
 CGATAGTTCTGGTCCCTTTGTTACTTACAGGTACCCCTGTTAAAGTACAGGTTACCTACATA
 1390 1400 1410 1420 1430 1440

THR GLY VAL TYR THR ASP ALA TYR PRO LEU ASN PRO THR GLY SER ILE VAL SER SER VAL
 AACAGGAGTATATGATGCCATATCCACTCAATCCCACAGGGAGGCATTGTTGTCATCTGT
 TTGTCCTCATATATGACTTACGGTATAAGGTAGGTGAGTTAGGGTACAGTGGCT
 1450 1460 1470 1480 1490 1500

ILE LEU ASP SER GLN LYS SER ARG VAL ASN PRO VAL ILE THR TYR SER THR [ALA] THR GLU
 CATATTAGATTCAAAATGGAAACGGAGAGAGGAGCTCAGTGGATATAACAAACAAAG
 GTATAATCTAAGTGGTTAGCTCAGTGGGTCACTTACGGTCACTTACGGTCACTTACGGT
 1510 1520 1530 1540 1550 1560

ARG VAL ASN GLU LEU ALA ILE [ARG] ASN ARG THR LEU SER ALA GLY TYR THR THR SER
 AAGAGTAAACGGAGGCTGCTGGCCATCCGAAACAGAACACTCTCAGGCTGATATAACAAACAAAG
 TTCTCATTTGGCTGGACCGGTTAGGCTTGTGAGTCAGCTATATGTTGTTGGCT
 1570 1580 1590 1600 1610 1620

FIG.3D.

CYS ILE THR HIS TYR ASN LYS GLY TYR CYS PHE HIS ILE VAL GLU ILE ASN **[GLN]** LYS SER
 CTGGCATCACACACTATAACAAAGGATATTGTTTCAATAGATAAGAAATAAAATCAGAAAAAG
 GACCTAAGTAGTTGTGATTGTTTCCCTATAACAAAGGATATTGTTTCAATAGCTTTC
 1630 1640 1650 1660 1670 1680

LEU **[ASN]** THR **[LEU]** GLN PRO MET LEU PHE LYS THR GLU **[VAL]** PRO LYS SER CYS SER ***
 CTAAACACACACTCAACCATTGTTCAAGAACAGAGGTTCCAAAAGCTGCAGTTAATC
 GAAATTGTTGAAAGTTGGGTACAAACAGTTCTGTCTCCAAAGGTTTTCGACGTCAAATTAG
 1690 1700 1710 1720 1730 1740

ATAAATTAAACGGCAATTACCTATGCCATTACCTATAACGTTATGTTAGATATTGTT
 ATTAAATTGGCGTTATACGGTATTCTGTTCTTCTTCTTCTT
 1750 1760 1770 1780 1790 1800

ATATCAGACATAAGACAAAGGGAAATAAAAAA
 TTAGCTCTTATCTGTTCTTCTTCTTCTT
 1810 1820 1830

11/39

NUCLEOTIDE SEQUENCE OF THE PIV-3 HN GENE. THE cDNA SEQUENCE IS SHOWN IN THE PLUS (mRNA) STRAND SENSE IN THE 5' TO 3' DIRECTION. THE TRANSMEMBRANE (TM) ANCHOR DOMAIN IS UNDERLINED. AMINO ACIDS DIFFERING FROM THE PUBLISHED PRIMARY SEQUENCE OF THE PROTEIN ENCODED BY THE PIV-3 HN GENE ARE BOXED.

FIG.3E.

12/39

RESTRICTION MAP OF THE PIV-3 HN GENE




FIG. 4.

FIG.5A. NUCLEOTIDE SEQUENCE OF THE RSV F GENE.

5' MET GLU LEU [PRO] ILE LEU LYS ALA ASN ALA ILE THR THR ILE LEU ALA [ALA] VAL THR PHE
ATGGAGTTGCCAATCCTCAAGCAATTACCAATCCTGGCTGCAGTCACATT
TACCTCAACGGTTAGGAGTTACGTTAACGTTAAATGGTTAGGAGGGACGGTCAAA
10 20 30 40 50 60

CYS PHE [ALA] SER GLN ASN ILE THR GLU GLU PHE TYR GLN SER THR CYS SER ALA VAL
TGCTTGCCTCTAGTCAAACATCACACTGAAAGAAATTACATGGCAGTGGCAGT
ACGAAACGAAAGATCAAGTTGTAGTGACTCTAAATAGTTAGTTACGGTCACGTCAA
70 80 90 100 110 120

SER LYS GLY TYR LEU SER ALA LEU ARG THR GLY TRP TYR THR SER VAL ILE THR ILE GLU
AGCAAAGGCTATCTTAGTGGCTCAAGAACCTGGTTAGTACTAGTGTATAACTATAAGAA
TCGTTCCGATAGAATCACCGAGATTCTGACCAACCATTGACATGATCACAAATTGATCTTT
130 140 150 160 170 180

LEU SER ASN ILE LYS GLU ASN LYS CYS ASN GLY THR ASP ALA LYS VAL LYS LEU [MET] LYS
TTAAGTAATAATCACAGGAAATAAGTGTAAATGGAAACAGATGCTAAGGGTAAATTGGATGAA
ATTCAATTAGTTCTCTTTTACATTACCTTACATTACGATTCTACGGATCTACGATT
190 200 210 220 230 240

GLN GLU LEU ASP LYS TYR LYS ASN ALA VAL THR GLU LEU LEU MET GLN SER THR
CAAGAATTAGATAATAAAATGCTGTAAACAGAAATTGGAGTTGCTCATGCAAAAGCACA
GTTCTTAACTTATTTACGACATTGCTTACGATTCTAACGGTCAACGGTACGGTTGGT
250 260 270 280 290 300

PRO [ALA] ASN ASN ASN ARG ARG GLU LEU PRO ARG PHE MET ASN TYR THR LEU ASN
CCAGCAGCAAAACATACTGGAGCCAGAAACTACCAAGGGTTATGAAATTACACTCAAC
GGTCGTCGTTGTTAGCTCTCTGGTACGGTTCCAAATACCTTAAATTGTGAGT
310 320 330 340 350 360

GLU GLY GLU VAL ASN LYS ILE LYS SER ALA LEU SER THR ASN LYS ALA VAL VAL SER
GAAGGAGAAAGTGAACAAAGATCAAAAGCTACTATCCACAAAGGGCGTAGTCAGT
CTTCCTTCACTTGTCTAGTTTCAGGAGATGATAAGGTTGTTCCGGCATCAGTCAGTCA
490 500 510 520 530 540

LEU SER ASN GLY VAL SER VAL THR SER LEU ASP LEU LYS ASN TYR ILE ASP
 T T A T C A A A T G G A G T T A G T G C T T A C C C A A G G T T A G A C C T C A A A A C T A T A G A T
 A A T A G T T A C C T C A A T C A C G A A T T G G T T C A C A T C T G G A G T T T G A T A T C A A
 550 560 570 580 590 600

LYS GLN LEU LEU PRO ILE VAL ASN LYS ARG SER CYS **[ARG]** ILE SER ASN ILE GLU THR VAL
 AACAAATTGTTACCTATTGTGAATAAGCGAAGCTGGAGATAAACATTAACACTTACGTTGACAC
 TTTGTTAACATTGGATAACATTGCTTCGACGTCATACTTGGACAC
 630 640 650 660
 610

ALA GLY VAL THR PRO VAL SER ILE
 6CAG GGT GAA CTG AACT ACAC TGG CACT GAT
 CGT CAC ATG ATG TGG GAC ATT CACT GAT
 730 740 750 760 770 780

ILE ASN ASP MET PRO ILE THR ASN ASP GLN LYS LYS LEU MET SER ASN ASN VAL GLN ILE
ATCAATGATACTACCCATAACAAATGATCAGAAAAAGTTAACATTGTTCAAATGTTCAAATGTTACAAGTTAT
TAGTTACTATACGGATATTTTCAATTACAGTTACAGGTACAAGTTAT 840
830 820

VAL ARG GLN GLN SER TYR SER ILE MET SER ILE ILE LYS GLU GLU VAL LEU ALA TYR VAL
GTTAGACAGCAAGGTTACCTACTATCATGTCCTACATAATAAAAGAGGAAGTCTAGGATACAGGTTCAAGTATACAT
CAATCTGTCTGGTTCAATGAGATAGTACAGGTT 890
880 870

VAL GLN LEU PRO LEU TYR GLY VAL ILE ASP THR PRO CYS TRP LYS LEU HIS THR SER PRO
GTTACAAATTACCACTATAATGGTTGATAGATAACCTTGTGGAAATTAACATCCTTAAATGTTGAGGGAA
CATGTTAAATGGTGTATACCAACACTATGTGAAACACCCTTAAATGTTGACTGTCCT 960
950 940

LEU CYS THR THR ASN THR LYS GLU GLY SER ASN ILE CYS LEU THR ARG THR ASP ARG GLY
CTATGTTACAAACACACAAAGAAAGGGTCAAAACATCTGTGTTAACAGAAATTTGAGACAAATTTGACTGTCCT 990
980 970

TRP TYR CYS ASP ASN ALA GLY SER VAL SER PHE PRO GLN ALA GLU THR CYS LYS VAL
TGGTACTGTGACAAATGCCAGGATCACAGTACCTTCTTCCACATGAAAGAAAGGGTTGACTGTCCT 1080
ACCATGACACTGTACGTTACGTTCTCCAGTTGTTGACTGTCCT 1070
1060 1050

GLN SER ASN ARG VAL PHE CYS ASP THR MET ASN SER LEU THR LEU PRO SER GLU [VAL] ASN
CAATCGAAATGGAGTATTGACACAAATGAAACAGTTAACATTACCAAGTGAAAGTAAT 1140
GTTAGCTTACGCTCATAAAACACACTGTGTTACTGTTCAATTTGTTCACTTCATTAA 1130
1120

LEU CYS ASN VAL ASP ILE PHE ASN PRO LYS TYR ASP CYS LYS ILE MET THR SER LYS THR
CTCTGCAATGTTGACATAATTCAATGCCAAATGAAATGACTTCACTGTTAGGTTACTAAACATTAAACATTAA 1190
GAGACGTTACACTGTATAAGTTAGGTTACTGAAAGTT 1180

FIG.5C.

TYR VAL SER ASN LYS GLY GLY [VAL] ASP THR VAL SER VAL GLY ASN THR LEU TYR TYR VAL ASN
 TAT GAT TCAAA TAAAGGGGTG GAC ACT GTG TCT GTG TAG GTAA CAC AT TAT ATT GTAA AT
 ATA CAT A GTT TTT CCCCCC ACC TTG TGA CAC AGAC AT CCATT GTAA TATA ACATT A
 |330 |340 |350 |360 |370 |380

LYS GLN GLU GLY LYS SER LEU TYR VAL LYS GLY PRO ILE ASN PHE TYR ASP PRO
 390
 AGCAAGAACAAAGTCTCATAAGGTTAAAGGTTGAACCAATAAAATCTATGACCCAA
 391
 TCGTTCTTCAGAGATAACATTTCACCTGGTTAAAGATACTGGT
 392
 |400
 |410
 |420
 |430
 |440
 |450

GLN	SER	LEU	ALA	PHE	ILE	ARG	LYS	SER	ASP	GLU	LEU	LEU	*	HIS	ASN	VAL	ASN	ALA	GLY	LYS
1510		1520		1530		1540		1550		1560				1570		1580		1590		1600

SER	THR	THR	ASN	ILE	MET	ILE	THR	THR	ILE	ILE	GLU	ILE	ILE	VAL	ILE	LEU	SER
TCA	ACC	CAA	AT	CAT	GAT	AAC	TAA	ACT	ATA	AT	AGA	TAT	ATG	ATT	TAT	TCA	TCA
AGT	TGG	TGT	TTA	ATG	ACT	TTA	CTT	ACT	TTA	TAT	GAT	TTA	TAT	CTA	ATA	ACA	ATG

1570 1580 1590 1600 1610 1620

SUBSTITUTE SHEET

FIG. 5D.

LEU ILE ALA VAL GLY LEU LEU TYR CYS LYS ALA ARG SER THR PRO VAL THR LEU SER
 TTATTGCTGGTTGGACTGCTCCCTACTGTAAAGGCCAGAACCAAGTCACACTAAAGC
 ATTAAACGACAAACCTGACCGAGGATATGACATTCGGTCTGTTGATTGAGTGGTGC
 1630 1640 1650 1660 1670 1680
 LYS ASP GLN LEU SER GLY ILE ASN ASN ILE ALA PHE SER ASN
 AGGATCAACTGAGTTGGTATAATAATGGCATTTAGTAACCTGAAATAAAATAGCACCT
 TCTCTAAGTGGACTCACCATTATTAACGTTAAATCATTGACTTATTCGTTGAG
 1690 1700 1710 1720 1730 1740
 ATCATGTTCTTACAATGGTTTACTATCTGCTCATAGACAAACCCATCTCATGGATT
 TTAGTACAAAGGAATGTTACCAAAATGATACTGGAGTATGTTGGTAACTAAAG
 1750 1760 1770 1780 1790 1800
 CCTTAAATCTGAAACTCATGGAAACTCTTATCTTAAACCAATCTCACTTACACTTTA
 AGAATTCTTAACTGACTTGAAGTAAAGTGAATGAGTAAATGGTAACTGATAAAAT
 1810 1820 1830 1840 1850 1860
 AGTAGATTCTAGTTTATAGTTATATCAATA
 TCATCTAAAGGATCAAATATCAATA
 1870 1880
 17/39
 17/40
 17/41
 17/42
 17/43
 17/44
 17/45
 17/46
 17/47
 17/48
 17/49
 17/50
 17/51
 17/52
 17/53
 17/54
 17/55
 17/56
 17/57
 17/58
 17/59
 17/60
 17/61
 17/62
 17/63
 17/64
 17/65
 17/66
 17/67
 17/68
 17/69
 17/70
 17/71
 17/72
 17/73
 17/74
 17/75
 17/76
 17/77
 17/78
 17/79
 17/80
 17/81
 17/82
 17/83
 17/84
 17/85
 17/86
 17/87
 17/88
 17/89
 17/90
 17/91
 17/92
 17/93
 17/94
 17/95
 17/96
 17/97
 17/98
 17/99
 17/100
 17/101
 17/102
 17/103
 17/104
 17/105
 17/106
 17/107
 17/108
 17/109
 17/110
 17/111
 17/112
 17/113
 17/114
 17/115
 17/116
 17/117
 17/118
 17/119
 17/120
 17/121
 17/122
 17/123
 17/124
 17/125
 17/126
 17/127
 17/128
 17/129
 17/130
 17/131
 17/132
 17/133
 17/134
 17/135
 17/136
 17/137
 17/138
 17/139
 17/140
 17/141
 17/142
 17/143
 17/144
 17/145
 17/146
 17/147
 17/148
 17/149
 17/150
 17/151
 17/152
 17/153
 17/154
 17/155
 17/156
 17/157
 17/158
 17/159
 17/160
 17/161
 17/162
 17/163
 17/164
 17/165
 17/166
 17/167
 17/168
 17/169
 17/170
 17/171
 17/172
 17/173
 17/174
 17/175
 17/176
 17/177
 17/178
 17/179
 17/180
 17/181
 17/182
 17/183
 17/184
 17/185
 17/186
 17/187
 17/188
 17/189
 17/190
 17/191
 17/192
 17/193
 17/194
 17/195
 17/196
 17/197
 17/198
 17/199
 17/200
 17/201
 17/202
 17/203
 17/204
 17/205
 17/206
 17/207
 17/208
 17/209
 17/210
 17/211
 17/212
 17/213
 17/214
 17/215
 17/216
 17/217
 17/218
 17/219
 17/220
 17/221
 17/222
 17/223
 17/224
 17/225
 17/226
 17/227
 17/228
 17/229
 17/230
 17/231
 17/232
 17/233
 17/234
 17/235
 17/236
 17/237
 17/238
 17/239
 17/240
 17/241
 17/242
 17/243
 17/244
 17/245
 17/246
 17/247
 17/248
 17/249
 17/250
 17/251
 17/252
 17/253
 17/254
 17/255
 17/256
 17/257
 17/258
 17/259
 17/260
 17/261
 17/262
 17/263
 17/264
 17/265
 17/266
 17/267
 17/268
 17/269
 17/270
 17/271
 17/272
 17/273
 17/274
 17/275
 17/276
 17/277
 17/278
 17/279
 17/280
 17/281
 17/282
 17/283
 17/284
 17/285
 17/286
 17/287
 17/288
 17/289
 17/290
 17/291
 17/292
 17/293
 17/294
 17/295
 17/296
 17/297
 17/298
 17/299
 17/300
 17/301
 17/302
 17/303
 17/304
 17/305
 17/306
 17/307
 17/308
 17/309
 17/310
 17/311
 17/312
 17/313
 17/314
 17/315
 17/316
 17/317
 17/318
 17/319
 17/320
 17/321
 17/322
 17/323
 17/324
 17/325
 17/326
 17/327
 17/328
 17/329
 17/330
 17/331
 17/332
 17/333
 17/334
 17/335
 17/336
 17/337
 17/338
 17/339
 17/340
 17/341
 17/342
 17/343
 17/344
 17/345
 17/346
 17/347
 17/348
 17/349
 17/350
 17/351
 17/352
 17/353
 17/354
 17/355
 17/356
 17/357
 17/358
 17/359
 17/360
 17/361
 17/362
 17/363
 17/364
 17/365
 17/366
 17/367
 17/368
 17/369
 17/370
 17/371
 17/372
 17/373
 17/374
 17/375
 17/376
 17/377
 17/378
 17/379
 17/380
 17/381
 17/382
 17/383
 17/384
 17/385
 17/386
 17/387
 17/388
 17/389
 17/390
 17/391
 17/392
 17/393
 17/394
 17/395
 17/396
 17/397
 17/398
 17/399
 17/400
 17/401
 17/402
 17/403
 17/404
 17/405
 17/406
 17/407
 17/408
 17/409
 17/410
 17/411
 17/412
 17/413
 17/414
 17/415
 17/416
 17/417
 17/418
 17/419
 17/420
 17/421
 17/422
 17/423
 17/424
 17/425
 17/426
 17/427
 17/428
 17/429
 17/430
 17/431
 17/432
 17/433
 17/434
 17/435
 17/436
 17/437
 17/438
 17/439
 17/440
 17/441
 17/442
 17/443
 17/444
 17/445
 17/446
 17/447
 17/448
 17/449
 17/450
 17/451
 17/452
 17/453
 17/454
 17/455
 17/456
 17/457
 17/458
 17/459
 17/460
 17/461
 17/462
 17/463
 17/464
 17/465
 17/466
 17/467
 17/468
 17/469
 17/470
 17/471
 17/472
 17/473
 17/474
 17/475
 17/476
 17/477
 17/478
 17/479
 17/480
 17/481
 17/482
 17/483
 17/484
 17/485
 17/486
 17/487
 17/488
 17/489
 17/490
 17/491
 17/492
 17/493
 17/494
 17/495
 17/496
 17/497
 17/498
 17/499
 17/500
 17/501
 17/502
 17/503
 17/504
 17/505
 17/506
 17/507
 17/508
 17/509
 17/510
 17/511
 17/512
 17/513
 17/514
 17/515
 17/516
 17/517
 17/518
 17/519
 17/520
 17/521
 17/522
 17/523
 17/524
 17/525
 17/526
 17/527
 17/528
 17/529
 17/530
 17/531
 17/532
 17/533
 17/534
 17/535
 17/536
 17/537
 17/538
 17/539
 17/540
 17/541
 17/542
 17/543
 17/544
 17/545
 17/546
 17/547
 17/548
 17/549
 17/550
 17/551
 17/552
 17/553
 17/554
 17/555
 17/556
 17/557
 17/558
 17/559
 17/560
 17/561
 17/562
 17/563
 17/564
 17/565
 17/566
 17/567
 17/568
 17/569
 17/570
 17/571
 17/572
 17/573
 17/574
 17/575
 17/576
 17/577
 17/578
 17/579
 17/580
 17/581
 17/582
 17/583
 17/584
 17/585
 17/586
 17/587
 17/588
 17/589
 17/590
 17/591
 17/592
 17/593
 17/594
 17/595
 17/596
 17/597
 17/598
 17/599
 17/600
 17/601
 17/602
 17/603
 17/604
 17/605
 17/606
 17/607
 17/608
 17/609
 17/610
 17/611
 17/612
 17/613
 17/614
 17/615
 17/616
 17/617
 17/618
 17/619
 17/620
 17/621
 17/622
 17/623
 17/624
 17/625
 17/626
 17/627
 17/628
 17/629
 17/630
 17/631
 17/632
 17/633
 17/634
 17/635
 17/636
 17/637
 17/638
 17/639
 17/640
 17/641
 17/642
 17/643
 17/644
 17/645
 17/646
 17/647
 17/648
 17/649
 17/650
 17/651
 17/652
 17/653
 17/654
 17/655
 17/656
 17/657
 17/658
 17/659
 17/660
 17/661
 17/662
 17/663
 17/664
 17/665
 17/666
 17/667
 17/668
 17/669
 17/670
 17/671
 17/672
 17/673
 17/674
 17/675
 17/676
 17/677
 17/678
 17/679
 17/680
 17/681
 17/682
 17/683
 17/684
 17/685
 17/686
 17/687
 17/688
 17/689
 17/690
 17/691
 17/692
 17/693
 17/694
 17/695
 17/696
 17/697
 17/698
 17/699
 17/700
 17/701
 17/702
 17/703
 17/704
 17/705
 17/706
 17/707
 17/708
 17/709
 17/710
 17/711
 17/712
 17/713
 17/714
 17/715
 17/716
 17/717
 17/718
 17/719
 17/720
 17/721
 17/722
 17/723
 17/724
 17/725
 17/726
 17/727
 17/728
 17/729
 17/730
 17/731
 17/732
 17/733
 17/734
 17/735
 17/736
 17/737
 17/738
 17/739
 17/740
 17/741
 17/742
 17/743
 17/744
 17/745
 17/746
 17/747
 17/748
 17/749
 17/750
 17/751
 17/752
 17/753
 17/754
 17/755
 17/756
 17/757
 17/758
 17/759
 17/760
 17/761
 17/762
 17/763
 17/764
 17/765
 17/766
 17/767
 17/768
 17/769
 17/770
 17/771
 17/772
 17/773
 17/774
 17/775
 17/776
 17/777
 17/778
 17/779
 17/780
 17/781
 17/782
 17/783
 17/784
 17/785
 17/786
 17/787
 17/788
 17/789
 17/790
 17/791
 17/792
 17/793
 17/794
 17/795
 17/796
 17/797
 17/798
 17/799
 17/800
 17/801
 17/802
 17/803
 17/804
 17/805
 17/806
 17/807
 17/808
 17/809
 17/810
 17/811
 17/812
 17/813
 17/814
 17/815
 17/816
 17/817
 17/818
 17/819
 17/820
 17/821
 17/822
 17/823
 17/824
 17/825
 17/826
 17/827
 17/828
 17/829
 17/830
 17/831
 17/832
 17/833
 17/834
 17/835
 17/836
 17/837
 17/838
 17/839
 17/840
 17/841
 17/842
 17/843
 17/844
 17/845
 17/846
 17/847
 17/848
 17/849
 17/850
 17/851
 17/852
 17/853
 17/854
 17/855
 17/856
 17/857
 17/858
 17/859
 17/860
 17/861
 17/862
 17/863
 17/864
 17/865
 17/866
 17/867
 17/868
 17/869
 17/870
 17/871
 17/872
 17/873
 17/874
 17/875
 17/876
 17/877
 17/878
 17/879
 17/880
 17/881
 17/882
 17/883
 17/884
 17/885
 17/886
 17/887
 17/888
 17/889
 17/890
 17/891
 17/892
 17/893
 17/894
 17/895
 17/896
 17/897
 17/898
 17/899
 17/900
 17/901
 17/902
 17/903
 17/904
 17/905
 17/906
 17/907
 17/908
 17/909
 17/910
 17/911
 17/912
 17/913
 17/914
 17/915
 17/916
 17/917
 17/918
 17/919
 17/920
 17/921
 17/922
 17/923
 17/924
 17/925
 17/926
 17/927
 17/928
 17/929
 17/930
 17/931
 17/932
 17/933
 17/934
 17/935
 17/936
 17/937
 17/938
 17/939
 17/940
 17/941
 17/942
 17/943
 17/944
 17/945
 17/946
 17/947
 17/948
 17/949
 17/950
 17/951
 17/952
 17/953
 17/954
 17/955
 17/956
 17/957
 17/958
 17/959
 17/960
 17/961
 17/962
 17/963
 17/964
 17/965
 17/966
 17/967
 17/968
 17/969
 17/970
 17/971
 17/972
 17/973
 17/974
 17/975
 17/976
 17/977
 17/978
 17/979
 17/980
 17/981
 17/982
 17/983
 17/984
 17/985
 17/986
 17/987
 17/988
 17/989
 17/990
 17/991
 17/992
 17/993
 17/994
 17/995
 17/996
 17/997
 17/998
 17/999
 17/1000
 17/1001
 17/1002
 17/1003
 17/1004
 17/1005
 17/1006
 17/1007
 17/1008
 17/1009
 17/1010
 17/1011
 17/1012
 17/1013
 17/1014
 17/1015
 17/1016
 17/1017
 17/1018
 17/1019
 17/1020
 17/1021
 17/1022
 17/1023
 17/1024
 17/1025
 17/1026
 17/1027
 17/1028
 17/1029
 17/1030
 17/1031
 17/1032
 17/1033
 17/1034
 17/1035
 17/1036
 17/1037
 17/1038
 17/1039
 17/1040
 17/1041
 17/1042
 17/1043
 17/1044
 17/1045
 17/1046
 17/1047
 17/1048
 17/1049
 17/1050
 17/1051
 17/1052
 17/1053
 17/1054
 17/1055
 17/1056
 17/1057
 17/1058
 17/1059
 17/1060
 17/1061
 17/1062
 17/1063
 17/1064
 17/1065
 17/1066
 17/1067
 17/1068
 17/1069
 17/1070
 17/1071
 17/1072
 17/1073
 17/1074
 17/1075
 17/1076
 17/1077
 17/1078
 17/1079
 17/1080
 17/1081
 17/1082
 17/1083
 17/1084
 17/1085
 17/1086
 17/1087
 17/1088
 17/1089
 17/1090
 17/1091
 17/1092
 17/1093
 17/1094
 17/1095
 17/1096
 17/1097
 17/1098
 17/1099
 17/1100
 17/1101
 17/1102
 17/1103
 17/1104
 17/1105
 17/1106
 17/1107
 17/1108
 17/1109
 17/1110
 17/1111
 17/1112
 17/1113
 17/1114
 17/1115
 17/1116
 17/1117
 17/1118
 17/1119
 17/1120
 17/1121
 17/1122
 17/1123
 17/1124
 17/1125
 17/1126
 17/1127
 17/1128
 17/1129
 17/1130
 17/1131
 17/1132
 17/1133
 17/1134
 17/1135
 17/1136
 17/1137
 17/1138
 17/1139
 17/1140
 17/1141
 17/1142
 17/1143
 17/1144
 17/1145
 17/1146
 17/1147
 17/1148
 17/1149
 17/1150
 17/1151
 17/1152
 17/1153
 17/1154
 17/1155
 17/1156
 17/1157
 17/1158
 17/1159
 17/1160
 17/1161
 17/1162
 17/1163
 17/1164
 17/1165
 17/1166
 17/1167
 17/1168
 17/1169
 17/1170
 17/1171
 17/1172
 17/1173
 17/1174
 17/1175
 17/1176
 17/1177
 17/1178
 17/1179
 17/1180
 17/1181
 17/1182
 17/1183
 17/1184
 17/1185
 17/1186
 17/1187
 17/1188
 17/1189
 17/1190
 17/1191
 17/1192
 17/1193
 17/1194
 17/1195
 17/1196
 17/1197
 17/1198
 17/1199
 17/1200
 17/1201
 17/1202
 17/1203
 17/1204
 17/1205
 17/1206
 17/1207
 17/1208
 17/1209
 17/1

NUCLEOTIDE SEQUENCE OF THE RSV F GENE.THE cDNA SEQUENCE IS SHOWN IN THE PLUS (+RNA) STRAND SENSE IN THE 5' TO 3' DIRECTION.THE SIGNAL PEPTIDE (SP) AND THE TRANSMEMBRANE (TM) ANCHOR DOMAIN ARE UNDERLINED.THE PREDICTED F2-F1 CLEAVAGE SITE IS INDICATED BY THE ARROW (↓).AMINO ACIDS DIFFERING FROM THE PUBLISHED PRIMARY SEQUENCE OF THE PROTEIN ENCODED BY THE RSV F GENE ARE BOXED.

۱۶۵

SUBSTITUTE SHEET

18/39

RESTRICTION MAP OF THE RSV F GENE




FIG. 6.

SUBSTITUTE SHEET

19/39

FIG.7A. NUCLEOTIDE SEQUENCE OF THE RSV G GENE

MET	SER	LYS	ASN	LYS	ASP	GLN	ARG		
T G C A A A C A T G T C C A A A A A C A A G G A C C A A C G									
A C G T T T G T A C A G G T T T G T T C C T G G T T G C									
10					20		30		
THR	ALA	LYS	THR	LEU	GLU	LYS	THR	TRP	ASP
C A C C G C T A A G A C A C T A G A A A A G A C C T G G G A									
G T G G C G A T T C T G T G A T C T T T C T G G A C C C T									
40					50			60	
THR	LEU	ASN	HIS	LEU	LEU	PHE	ILE	SER	SER
C A C T C T C A A T C A T T A T T A T T C A T A T C A T C									
G T G A G A G T T A G T A A A T A A T A A G T A T A G T A G									
70					80			90	
GLY	LEU	TYR	LYS	LEU	ASN	LEU	LYS	SER	VAL
G G G C T T A T A A G T T A A A T C T T A A A T C T G T									
C C C G A A T A T A T T C A A T T T A G A A T T T A G A C A									
100					110			120	
<hr/> TM <hr/>									
ALA	GLN	ILE	THR	LEU	SER	ILE	LEU	ALA	MET
A G C A C A A A T C A C A T T C A C T T C A T T C T G G C A A T									
T C G T G T T A G T G T A A T A G G T A A G A C C G T T A									
130					140			150	
ILE	ILE	SER	THR	SER	LEU	ILE	ILE	THR	ALA
G A T A A T C T C A A C T T C A C T T A T A A T T A C A G C									
C T A T T A G A G T T G A A G T G A A T A T T A A T G T C G									
160					170			180	
ILE	ILE	PHE	ILE	ALA	SER	ALA	ASN	HIS	LYS
C A T C A T A T T C A T A G G C T C G G G C A A A C C C A C A A									
G T A G T A T A A G T A T C G G G A G C C G T T T G G T G T T									
190					200			210	
VAL	THR	LEU	THR	THR	ALA	ILE	ILE	GLN	ASP
A G T C A C A C T A A C A A C T G C A A T C A T A C A A G A									
T C A G T G T G A T G T T G A C G T T A G T A T G T C T									
2					230			240	
ALA	THR	SEI	GLN	ILE	LYS	ASN	THR	THR	PRO
T G C A A C A A G			C A G A T C A A G G A A C A C A A C C C C						
A C G T T G T T C			G T C T A G T T C T T G T G T T G G G G						
260			270						
THR	TYR	LEU	THR	GLN	ASP	PRO	GLN	LEU	GLY
A A C A T A C C T C A C T C A G G A T C C C T C A G G C T T G G									
T T G T A T G G A G T G A G T C C T A G G A G T C G A A C C									
280			290						300

20/39

FIG.7B.

ILE SER **PHE** SER ASN **LEU** SER GLU ILE THR
 AAT CAG CTT CTCCAATCTGTCTGAAATTAC
 TTAGTCGAAGAGGTTAGACAGACTTTAATG
 310 320 330

SER GLN **THR** THR THR ILE LEU ALA SER THR
 ATCACAAACCAACCACCATACTAGCTTCAAAC
 TAGTGGTTGGTGGTATGATCGAAGTTG
 340 350 360

THR PRO GLY VAL LYS SER **ASN** LEU GLN **PRO**
 AACACCCAGGAGTCAAGTCAAACCTGCAAC
 TTGGTGGTCCTCAGTTCAAGTTGGACGTTGG
 370 380 390

THR THR VAL LYS THR LYS ASN THR THR THR
 CACAACAGTCAAGACTAAAAAACACAACAAAC
 GTGTTGTCAGTTCTGATTTTGTTGTTGTTG
 400 410 420

THR GLN THR GLN PRO SER LYS PRO THR THR
 AACCCAAACACAACCCAGCAAGGCCCACTAC
 TTGGGTTGGTGGTCTGGTTGGGTGATG
 430 440 450

LYS GLN ARG GLN ASN LYS PRO PRO **ASN** LYS
 AAAAACAAACGCCAAAAACAAACCCACCAACAA
 TTTTGTTGCGGTTTGTTGGTTGGTTGTT
 460 470 480

PRO ASN ASN ASP PHE HIS PHE GLU VAL PHE
 ACCCAATAATGATTTCACCTCGAAAGTGT
 TGGTTATTACTAAAAGTGAAGCTTCACAA
 490 500 510

ASN PHE VAL PRO CYS SER ILE CYS SER ASN
 TAACCTTGTAACCCCTGCAAGCATATGCAAGCAA
 ATTGAAACATGGGACGTCGTATACGTCGTT
 520 530 540

ASN PRO THR CYS TRP ALA ILE CYS LYS ARG
 CAATCCAAACCTGCTGGGCTATCTGCACAAAG
 GTTAGGTTGGACGACCCGATAGACGTTTC
 550 560 570

ILE PRO ASN LYS LYS PRO GLY LYS LYS THR
 AATACCAAAACAAAAACCCAGGAAAGAAAC
 TTATGGTTGTTTTGTGCTCTTCTTT
 580 590 600

21/39

FIG.7C.

THR THR LYS PRO THR LYS LYS PRO THR PHE
 C A C C A C C A A G C C T A C A A A A A A A C C A A C C T T
 G T G G T G G T T C G G A T G T T T T T G G T T G G A A
 610 620 630

LYS THR THR LYS LYS ASP **LEU** LYS PRO GLN
 C A A G A C A A C C A A A A A A G A T C T C A A A C C T C A
 G T T C T G T T G G T T T T C T A G A G T T T G G A G T
 640 650 660

THR THR LYS **PRO** LYS GLU VAL PRO THR THR
 A A C C A C T A A A C C A A A G G A A G T A C C C A C C A C
 T T G G T G A T T T G G T T C C T C A T G G G T G G T G
 670 680 690

LYS PRO THR GLU GLU PRO THR ILE ASN THR
 C A A G C C C A C A G A A G G A G C C A A C C A T C A A C A C
 G T T C G G G T G T C T T C T C G G T T G G T A G T T G T G
 700 710 720

THR LYS THR ASN ILE **THR** THR THR LEU LEU
 C A C C A A A A C A A A C A T C A C A A C T A C A C T G C T
 G T G G T T T G T T G T A G T G T T G A T G T G A C G A
 730 740 750

THR **ASN** ASN THR THR GLY ASN PRO **LYS** LEU
 C A C C A A C A A C A C C A C A G G A A A T C C A A A A C T
 G T G G T T G T G G T G T C C T T T A G G T T T T G A
 760 770 780

THR SER GLN MET GLU THR PHE HIS SER THR
 C A C A A G T C A A A T G G A A A C C T T C C A C T C A A C
 G T G T T C A G T T A C C T T G G A A G G T G A G T T G
 790 800 810

SER SER GLU GLY ASN **LEU** SER PRO SER GLN
 C T C C T C C G A A G G C A A T C T A A G G C C C T T C T C A
 G A G G A G G C T T C C G T T A G A T T C G G G A A G A G T
 820 830 840

VAL SER THR THR SER GLU **HIS** PRO SER GLN
 A G T C T C C A C A A C A T C C G A G G C A C C C A T C A C A
 T C A G A G G T G T T G T A G G C T C G T G G G T A G T G T
 850 860 870

PRO SER SER PRO PRO ASN THR **THR** ARG GLN
 A C C C T C A T C T C C A C C C A A C A C A A C A C G C C A
 T G G G A G T A G A G G T G G G T T G T G T T G T G C G G G T
 880 890 900

22/39

G T A G T T A T T A A A A A A A A A A
C A T C A A T A A T T T T T T T T T T
910 920

NUCLEOTIDE SEQUENCE OF THE RSV G GENE. THE cDNA
SEQUENCE IS SHOWN IN THE PLUS (mRNA) STRAND
SENSE IN THE 5' TO 3' DIRECTION. THE TRANSMEMBRANE
(TM) ANCHOR DOMAIN IS UNDERLINED. AMINO ACIDS
DIFFERING FROM THE PUBLISHED PRIMARY SEQUENCE OF
THE PROTEIN ENCODED BY THE RSV G GENE ARE BOXED.

FIG.7D.

23/39

RESTRICTION MAP OF RSV G GENE




FIG. 8.

24/39

Construction of a Bluescript-based expression vector containing the chimeric PIV-3 -F RSV gene with the 5' untranslated region of the PIV-3 F gene intact but lacking the nucleotide sequences coding for the hydrophobic anchor domains and cytoplasmic tails of both the PIV-3 and RSV F genes.

Step 1: Preparation of the plasmid containing the modified PIV-3 F gene





FIG.9A.

25/39

FIG. 9B. Step 2: Preparation of the plasmid containing the modified RSV F gene promoter

26/39




FIG. 9C.

27/39





FIG. 9D.

28/39

Construction of a Bluescript-based expression vector containing the PIV-3 F gene lacking the 5' untranslated sequence and transmembrane anchor and cytoplasmic tail coding regions.




Retrieval 1.6 Kb [BamHI] - BsrI PIV-3 F gene fragment

BsrI
5' ACTGGCATCAAATCTAGCACTACATGAG ... 3'
----- CGTAGTTAGATCGTGATGTACTCCCTAG -----

FIG.10A.

29/39

FIG.10B.



Cut with EcoRI and BstBI


Retrieve: EcoRI-BstBI restricted vector

Ligate: EcoRI-BstBI restricted vector +

EcoRI

AATT CATGCCAACTTAATAC TGCTAATTATTACAACAAATGATTATGG
 CATCTT CCTGCCAAATAGATATCACAAA ACTACAGCAATGTAGGGTGA
 TTGGTCAACAGTCCCAAAGGGATGAAGATATCACAAA ACTT
 --- GTACGGTTGAAATTATGACGATTAATAATGTTGTTACTAATACC
 GTAGAAGGACGGTTATCTATAGTGTGTTGATGTCGTACATCCACATA
 ACCAGTTGTCAGGGTTCCCTACTTCTATAGTGTGTTGAAGCTT

PpuMI



30/39

Construction of the chimeric F PIV-3-F RSV gene consisting of the truncated PIV-3 F gene devoid of the 5' untranslated region linked to the truncated RSV F1 gene.





FIG. II.

31/39

FIG.12A. Construction of the modified pAC 610 baculovirus expression vector containing the chimeric PIV-3'-RSV gene consisting of the PIV-3' F gene lacking both the 5' untranslated sequence as well as the transmembrane and cytoplasmic tail coding regions linked to the truncated RSV F1 gene T7 promoter



32/39




FIG.12B.

33/39

FIG.13

IMMUNOBLOTS OF CELL LYSATES FROM SF9 CELLS
INFECTED WITH RECOMBINANT BACULOVIRUSES






FIG 13 : Immunoblots of cell lysates from SF9 cells infected with recombinant baculoviruses containing the truncated RSV F gene (Lane 1), the chimeric F_{PIV-3}-F_{RSV} gene (Lane 2) or infected with wild type virus (Lane 3) reacted with anti-F RSV Mab (panel A) and anti-F1 PIV-3 antiserum (panel B)

34/39

FIG.14. CONSTRUCTION OF THE BACULOVIRUS TRANSFER VECTOR pD2




35/39

FIG.15 A. CONSTRUCTION OF THE RSV-HN PIV₃ CHIMERIC GENE

36/39

FIG.15B.



37/39

FIG.16

SDS POLY ACRYLAMIDE GEL AND IMMUNOBLOTS OF PURIFIED FRSV-HNPIV-3 CHIMERIC PROTEIN





FIG.16 : A) Coomassie-stained SDS polyacrylamide gel of immunoaffinity-purified FRSV-HNPIV-3 protein.


B) Immunoblots of FRSV-HNPIV-3 protein reacted with an anti-F RSV Mab (lane 1) and anti-HN PIV-3 antiserum (lane 2)

38/39

FIG.17. MUTAGENESIS OF THE PIV-3 F GENE



39/39

FIG.18. CONSTRUCTION OF THE F_{PIV3}-G_{RSV} CHIMERIC GENE

INTERNATIONAL SEARCH REPORT

PCT/CA 93/00001

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 C12N15/45; A61K39/155; G01N33/569

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System	Classification Symbols		
Int.Cl. 5	C12N ;	A61K ;	G01N

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	J. VIROL. vol. 64, no. 8, 1990, pages 4007 - 4012 P. COLLINS 'O glycosylation of glycoprotein g of human respiratory syncytial virus is specified within the divergent ectodomain' see the whole document ---	1-11, 13, 16-26, 28, 29, 32-35, 39-47, 53
X	MOL. CELL. BIOL. vol. 8, no. 4, 1988, pages 1709 - 1714 S. VIJAYA ET AL. 'Transport to the cell surface of a peptide sequence attached to the truncated C terminus of an n-terminally anchored integral membrane protein' see page 1713 ---	1-4, 6, 16-21, 28, 32-36, 39-43, 48-54, 56-58 -/-

¹⁰ Special categories of cited documents :¹⁰

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

¹¹ T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

¹² X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

¹³ Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

¹⁴ & document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

13 MAY 1993

Date of Mailing of this International Search Report

03.06.93

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

SKELLY J.M.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	WO,A,8 910 405 (THE UPJOHN COMPANY) 2 November 1989 cited in the application see the whole document ---	1-58
Y	WO,A,8 905 823 (THE UPJOHN COMPANY) 29 June 1989 cited in the application see the whole document ---	1-58
A	J. GEN. VIROL. vol. 70, 1989, pages 2637 - 2644 R. BRIDEAU ET AL. 'Protection of cotton rats against human respiratory syncytial virus' cited in the application ---	
A	J. GEN. VIROL. vol. 70, 1989, M. WATHEN ET AL. 'Characterisation of a novel human respiratory syncytial virus chimeric FG glycoprotein' cited in the application -----	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA93/00001

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 54-56 are directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.

CA 9300001
SA 68995

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 13/05/93

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-8910405	02-11-89	AU-B-	611784	20-06-91
		AU-A-	3197589	24-11-89
		CA-A-	1306709	25-08-92
		EP-A-	0413695	27-02-91
		US-A-	5169628	08-12-92
WO-A-8905823	29-06-89	AU-A-	2785089	19-07-89
		DE-A-	3878468	25-03-93
		EP-A, B	0396563	14-11-90
		US-A-	5194595	16-03-93